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BACKGROUND 
 
Mania is a condition of excessively raised mood that affects about 1% of the population, 
usually occurs in association with episodes of depression, and defines the diagnosis of 
bipolar disorder. Bipolar disorder is a chronic, disabling and heterogeneous condition, 
and one of the leading causes of worldwide disability and poor quality of life, especially 
in those aged 15–44 years. A manic episode is defined as a period of seven or more days 
(or any period if admission to hospital is required) of unusually and continuously 
effusive and open elated or irritable mood, where the mood is not caused by drugs 
assumption or a medical illness (e.g., hyperthyroidism), and is causing difficulties at 
work or in social relationships and activities, or requires admission to hospital to protect 
the person or others, or the person is suffering psychosis (APA, 2000). To be classed as a 
manic episode, while the disturbed mood is present at least three (or four if only 
irritability is present) of the following must have been consistently prominent: grand or 
extravagant style, or expanded self-esteem; reduced need of sleep (e.g. three hours may 
be sufficient); talks more often and feels the urge to talk longer; ideas flit through the 
mind in quick succession, or thoughts race and preoccupy the person; over indulgence 
in enjoyable behaviors with high risk of a negative outcome (e.g., extravagant shopping, 
sexual adventures or improbable commercial schemes) (APA, 2000).  
The World Health Organization's classification system defines a manic episode as one 
where mood is higher than the person's situation warrants and may vary from relaxed 
high spirits to barely controllable exuberance, accompanied by hyperactivity, a 
compulsion to speak, a reduced sleep requirement, difficulty sustaining attention and, 
often, increased distractibility (WHO, 1993). Frequently, confidence and self-esteem are 
excessively enlarged, and grand, extravagant ideas are expressed. Behavior that is out of 
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character and risky, foolish or inappropriate may result from a loss of normal social 
restraint. Some people also have physical symptoms, such as sweating, pacing, and 
weight loss.  
The main aim in treating mania, hypomania and mixed episodes is to achieve rapid 
control of symptoms. This is particularly important as mania can result in disturbed 
behavior that, when extreme, can be a risk to the safety of the patient and others. Despite 
the availability of many efficacious pharmacological treatments for mania and 
hypomania, their management in clinical settings remains a challenge. Mood stabilizers 
and antipsychotic agents have long been the mainstay of treatment of acute mania, with 
and without psychotic features (NICE, 2006; Scherk et al., 2007).  
Lithium and valproate are held to be effective in acute mania but their onset of action is 
slower than with antipsychotics. Prior to the introduction of the atypical antipsychotics, 
the conventional antipsychotics were the frequently used treatment for mania despite a 
relative lack of randomized controlled trials to support their use. In recent years several 
atypical antipsychotics agents have been licensed to treat mania (aripiprazole, 
olanzapine, risperidone and quetiapine). However, there is a debate about the benefits of 
newer so-called atypical antipsychotic drugs compared with older antipsychotic drugs. 
A major advantage of the atypical antipsychotics over conventional antipsychotics is the 
lower risk of extrapyramidal symptoms (EPS) though this differential has largely been 
demonstrated in trials where the comparator was haloperidol, a high-potency 
conventional antipsychotic that is associated with a relatively high incidence of EPS.  
There is no general consensus about which of these drugs should be used first-line. 
Guidelines for the treatment of bipolar disorder vary significantly across committees or 
specialist groups (Fountoulakis et al., 2005). In particular for the treatment of acute 
mania, some guidelines recommend monotherapy with a mood stabilizer or an 
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antipsychotic drug as first-line treatment, whereas others recommend a combination of a 
mood stabilizer and an antipsychotic agent. Adverse effects in short term studies tend to 
focus on EPS but some atypical antipsychotics, in particular olanzapine and clozapine, 
are associated with a high risk of significant increase in body weight and this may 
influence the selection even of short term treatments under some circumstances.  
For clinical conditions where many treatment regimens already exist, competing with 
each other, the real question is how to rank their benefits (and harms) to choose the best 
option. This has led to the development of meta-analytical techniques that allow the 
incorporation of evidence from direct and indirect comparisons toward estimating 
summary treatment effects.  
Multiple treatments meta-analysis (MTM) is a statistical technique that allows both 
direct and indirect comparisons to be undertaken, even when two of the treatments have 
not been directly compared (Salanti et al., 2011, Higgins et al., 1996; Hasselblad et al., 
1998; Lumley, 2002) (Figure 1). MTM has already been used successfully in many fields 
of medicine (Psaty et al., 2003; Elliott et al., 2007; Cipriani et al., 2009). Two fruitful roles 
for MTM have been identified (Lu and Ades 2004):  
(i)  to strengthen inferences concerning the relative efficacy of two treatments, by 
including both direct and indirect comparisons to increase precision and combine 
both direct and indirect evidence (Salanti et al., 2008);  
(ii)  to facilitate simultaneous inference regarding all treatments in order for example 
to select the best treatment.  
Considering how important comparative efficacy could be for clinical practice and 
policy making, it is useful to use all the available evidence to estimate potential 
differences in efficacy among treatments. MTM rely on a strong assumption that studies 
of different comparisons are similar in all ways other than the interventions being 
 5 
 
compared. The indirect comparisons involved are not randomized comparisons, and 
may suffer the biases of observational studies, for example due to confounding. In 
situations when both direct and indirect comparisons are available in a review, any use 
of multiple-treatments meta-analyses should be to supplement, rather than to replace, 
the direct comparisons. Expert statistical support, as well as subject expertise, is required 
for carrying out and interpreting multiple treatments meta-analyses.  
 
 
FIGURE 1. Graphic explanation on indirect comparisons to be used in MTM (see text).   
 
The aim of this study was to compare the efficacy and acceptability of pharmacological 
treatments for acute mania, either against placebo or against one another, in order to 
inform clinical practice and mental health policies.  We carried out a MTM. Reliable 
information on comparative efficacy is essential for informing clinical practice and 
policy making and MTM allows us to use all the available evidence to estimate potential 
differences in efficacy among treatments. 
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METHODS 
 
OBJECTIVES 
To compare individual anti-manic agents in terms of efficacy (both dichotomous and 
continuous measures) and acceptability (drop-out rate). 
 
TYPES OF STUDIES 
Double-blind randomised controlled trials (RCTs) comparing one active drug 
(antipsychotic, mood stabiliser or benzodiazepine) with another active drug 
(antipsychotic, mood stabiliser or benzodiazepine) or placebo as oral therapy in the 
treatment of acute mania were included. All combination studies (when combining 
drugs of the same class, for instance antipsychotic plus antipsychotic) and augmentation 
studies (when combining drugs belonging to different classes, for instance antipsychotic 
plus mood stabiliser) were included as well. We therefore investigated heterogeneity 
between these different types of studies. Quasi-randomized trials (such as those 
allocating by using alternate days of the week) were excluded. For trials which have a 
crossover design, only results from the first randomisation period were considered.  
 
TYPES OF PARTICIPANTS 
Patients aged 18 or older of both sexes with a primary diagnosis of acute mania or 
bipolar disorder (manic or mixed episode) according to the standardised diagnostic 
criteria used by the study authors. Most recent studies used DSM-IV (APA 1994) or ICD-
10 (WHO 1992) criteria. Older studies used ICD-9 (WHO 1978), DSM-III (APA 
1980)/DSM-III-R (APA 1987) or other diagnostic systems such as Feighner criteria or 
Research Diagnostic Criteria. There is no evidence that treatment effects differ 
depending on the diagnostic criteria used. A concurrent Axis I diagnosis of another 
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psychiatric disorder was considered as exclusion criteria. A concurrent Axis II diagnosis 
of psychiatric disorder was not considered as exclusion criteria. Studies with patients 
with a serious concomitant medical illness as an inclusion criterion were excluded.  
 
OUTCOME MEASURES 
 
(1) Overall efficacy of treatment  
1.1  Overall efficacy was primarily measured as the mean change of the total score of 
the Young Mania Rating Scale (YMRS) from baseline to endpoint. If YMRS results 
were not available, we used the mean change from baseline to endpoint of other 
standardised rating scales for acute mania.    
1.2  We also estimated efficacy as the proportion of patients who responded to 
treatment (response was defined as a reduction of at least 50% on the total score 
between baseline and endpoint on a standardized rating scale for mania possibly 
YMRS; if not available, other rating scales were used). 
 
(2) Acceptability of treatment 
2.1  Treatment discontinuation (acceptability) was defined as the proportion of 
patients who left the study early for any reason, out of the total number of patients 
randomly assigned to each treatment arm. 
 
SEARCH STRATEGY 
All published and unpublished randomized controlled, double-blind trials that 
compared oral doses of one of the above mentioned anti-manic drugs with another drug 
(or placebo) in the treatment of acute mania were identified (full details on the search 
strategy reported in Appendix 1). We identified relevant trials from systematic searches 
in the following electronic databases, MEDLINE, EMBASE, CINAHL, PsycINFO, and 
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the Cochrane Central Register of Controlled Trials. We also consulted trial databases of 
the following drug-approving agencies - (the Food and Drug Administration in the US, 
the Medicines and Healthcare products Regulatory Agency in the UK, the European 
Medicines Agency in the EU, the Pharmaceuticals and Medical Devices Agency in Japan, 
the Therapeutic Goods Administration in Australia and ongoing trial registers 
(clinicaltrials.gov in the USA, National Research Register in the UK, Netherlands Trial 
Register in the Netherlands, EUDRACT in the EU, UMIN-CTR in Japan and the 
Australian Clinical Trials Registry in Australia) was hand-searched for published, 
unpublished and ongoing controlled trials. No language restrictions were applied.  
Electronic databases were searched using the following strategy: [bipolar disorder or 
bipolar depression or mania or manic or hypomania or cyclothymic cycle or ultra-rapid 
cycling or ultradian cycling or RCBD or DMX or mixed depression or mixed bipolar or 
reactive depression or psychogenic depression or puerperal psychosis or puerperium 
psychosis or excited psychosis] and combined with a list of antipsychotics, including 
[(amisulpride or aripiprazole or benperidol or chlorpromazine  or chlorprothixene  or 
clozapine  or flupentixol  or fluspirilene  or haloperidol  or levomepromazine  or 
olanzapine  or paliperidone  or pericyazine or perphenazine or pimozide  or 
prochlorperazine  or promazine  or quetiapine  or risperidone or sertindole or sulpiride 
or trifluoperazine or zotepine) or mood stablisers, including (alprazolam or 
bromazepam or carbamazepine  or chlordiazepoxide  or clobazam or clonazepam or 
clorazepate  or delorazepam  or diazepam  or ethosuximide  or flunitrazepam  or 
flurazepam or flutoprazepam or gabapentin  or lacosamide  or lamotrigine  or 
levetiracetam  or lithium or loprazolam  or lorazepam  or lormetazepam  or mexazolam  
or midazolam  or nitrazepam  or oxazepam or oxcarbazepine  or phenobarbital  or 
phenytoin  or prazepam or pregabalin  or temazepam or tiagabine  or topiramate  or 
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valproic acid  or verapamil  or vigabatrin  or zonisamide)]. All relevant authors and 
principal manufacturers were contacted to supplement the incomplete report of the 
original papers. We also checked the websites of these manufacturers for further studies.  
 
STUDY SELECTION AND DATA EXTRACTION  
According to study protocol, we used the data that have been extracted for the previous 
Cochrane reviews carried out by the members of our review team (see Appendix 2). 
Concerning the update search, three reviewers independently reviewed references and 
abstracts. If both reviewers agreed that the trial did not meet eligibility criteria, we 
excluded it. We obtained the full text of all remaining articles and used the same 
eligibility criteria to determine which, if any, to exclude at this stage. Any disagreements 
were solved via discussion with another member of the reviewing team. The same 
reviewers then independently readed each article, evaluated the completeness of the 
data abstraction, and confirmed the quality rating. As for previous Cochrane systematic 
reviews, we designed and used a structured data abstraction form to ensure consistency 
of appraisal for each study. Information extracted included study characteristics (such as 
lead author, publication year, journal, study setting, sponsorship), participant 
characteristics (such as diagnostic criteria, mean baseline score, age), intervention details 
(such as dose ranges, mean doses of study drugs, concomitant and/or rescue 
medications) and outcome measures (see above).  
 
LENGTH OF FOLLOW UP 
In the present review, acute treatment was defined as a 3-week treatment in all analyses. 
If 3-week data were not available, we used data ranging between 2 and 6 weeks (we 
given preference to the time-point given in the original study as the study endpoint).  
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QUALITY ASSESSMENT 
Two independent review authors assessed study quality using the Cochrane risk of bias 
tool (Higgins et al., 2011). This instrument consists of six items, providing a framework 
for assessing the whole trial with explicit and transparent judgmental separating the 
facts from the judgments. Two of the items (adequacy of sequence generation and al 
location concealment) assess the strength of the randomization process in preventing 
selection bias in the assignment of participants to interventions; the third item (blinding) 
assesses the influence of performance bias on the study results and the fourth the 
likelihood of incomplete outcome data, which raise the possibility of bias in effect 
estimates. The fifth item assesses selective reporting, the tendency to preferentially 
report statistically significant outcomes (this item requires a comparison of published 
data with trial protocols, when such are available). The final item refers to other sources 
of bias that are relevant in certain circumstances, such as, for example, sponsorship bias. 
Where inadequate details of allocation concealment and other characteristics of trials 
were provided, the trial authors were contacted in order to obtain further information. If 
the raters disagreed, the final rating was made by consensus with the involvement (if 
necessary) of another member of the review group. 
 
COMPARABILITY OF DOSAGES 
We included only studies randomizing patients to drugs within the therapeutic dose 
(both fixed-dose and flexible-dose designs were allowed). There was the possibility that 
some trials compared one agent at the upper limit of its therapeutic range with another 
agent at the lower limit of its therapeutic range within the same study. We looked at 
heterogeneity and then added a variable (yes/no) that reported if dosages were 
comparable and use this information for analysis.   
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STATISTICAL ANALYSIS 
The efficacy outcome of this review was the change of the total score of the YMRS. 
Dichotomous outcomes were analysed on an intention-to-treat (ITT) basis: drop-outs 
were always included in this analysis. When data on drop-outs were carried forward 
and included in the evaluation (Last Observation Carried Forward, LOCF), they were 
analysed according to the primary studies.   
 
SYNTHESIS OF RESULTS 
We generated descriptive statistics for trial and study population characteristics across 
all eligible trials, describing the types of comparisons and some important variables, 
either clinical or methodological (such as year of publication, age, severity of illness, 
sponsorship). For each pair-wise comparison between anti-manic drugs, the 
standardized mean difference (SMD) was calculated as the effect size for continuous 
outcomes and the odds ratio was calculated for dichotomous outcomes, both with a 95% 
CI. We first performed pair-wise meta-analyses by synthesizing studies that compare the 
same interventions using a random effects model (DerSimonian & Laird, 1986) to 
incorporate the assumption that the different studies were estimating different, yet 
related, treatment effects (Higgins & Green, 2006). Visual inspection of the forest plots 
was used to investigate the possibility of statistical heterogeneity. This was 
supplemented using, primarily, the I-squared statistic. This provides an estimate of the 
percentage of variability due to heterogeneity rather than a sampling error (Higgins et 
al., 2003). 95% confidence intervals was calculated for I-squared, and a P value from a 
standard test for heterogeneity was used to assess evidence of its presence.  
We conducted a MTM which is a method of synthesizing information from a network of 
trials addressing the same question but involving different interventions. For a given 
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comparison, say A versus B, direct evidence is provided by studies that compare these 
two treatments directly. However, indirect evidence is provided when studies that 
compare A versus C and B versus C are analyzed jointly. The combination of the direct 
and indirect into a single effect size can increase precision while randomization is 
respected. The combination of direct and indirect evidence for any given treatment 
comparison can be extended when ranking more than three types of treatments 
according to their effectiveness: every study contributes evidence about a subset of these 
treatments.  
We performed MTM within a Bayesian framework (Ades et al., 2006). This enabled us to 
estimate the probability for each intervention to be the best for each positive outcome, 
given the results of the MTM.  
The analysis was performed using WinBUGS (MRC Biostatistics Unit, Cambridge, U.K., 
http://www.mrcbsu.cam.ac.uk/bugs/winbugs/contents.shtml ).  
MTM should be used carefullly, and the underlying assumptions of the analysis should 
be investigated carefully. Key among these is that the network is coherent, meaning that 
direct and indirect evidence on the same comparisons agree. Joint analysis of treatments 
can be misleading if the network is substantially incoherent, i.e., if there is disagreement 
between indirect and direct estimates. So, as a first step, we calculated the difference 
between indirect and direct estimates in each closed loop formed by the network of trials 
as a measure of incoherence and we subsequently examined whether there are any 
material discrepancies. In case of significant incoherence we investigated possible 
sources of it. Incoherence may result as an uneven distribution of effect modifiers across 
groups of trials that compare different treatments. Therefore, we investigated the 
distribution of clinical and methodological variables that we suspected may be potential 
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sources of either heterogeneity or incoherence in each comparison-specific group of 
trials. 
 
SUBGROUP AND META-REGRESSION ANALYSES 
We carried out a subgroup analysis based on the type of study treatment 
(combination/augmentation treatments vs monotherapy) and a meta-regression analysis 
for sponsorship (Salanti et al., 2009). 
 
 
RESULTS 
 
The electronic searches yielded 582 potentially relevant studies. Of all these items, 188 
potentially eligible articles were analysed. We excluded 125 reports that did not meet 
eligibility criteria. A further 9 unpublished trials eligible for the MTM were identified 
from searching websites of pharmaceutical industries. Overall, 68 trials from 1980 to 
2010 were available and were used for the MTM (Figure 2). For references to included 
studies see the reference list at the end of the document.  
In total, 14 treatments were analysed: aripiprazole, asenapine, carbamazepine, valproate, 
gabapentin, haloperidol, lamotrigine, lithium, olanzapine, paliperidone, quetiapine, 
risperidone, topiramate, ziprasidone, and placebo. Most trials (54 of 68, 79%) were two-
grouped studies and the rest were three-grouped studies in which one active 
comparator was usually haloperidol. 17 trials had a combination design, in which the 
anti-manic drugs of interest were added to lithium or valproate. Of these trials, only one 
was a three-grouped study and the remaining 16 were two-grouped (see Appendix 3). 
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398 articles excluded after initial screening of titles and abstracts
4 unpublished studies (from pharmaceutical industry websites) 
129 full-text articles excluded after detailed screening
19 duplicates
18 meeting abstracts (unable to extract any data)
26 non-randomised design
9 comparing with non-oral formulation of anti-manic drugs
3 full text unavailable
13 unable to extract any reliable data
37 reviews or pooled-analyses
4 RCTs could not be included in the network (no usable data)
68 randomised controlled trials (RCTs) included in the multiple treatment meta-analysis*
7 RCTs comparing aripiprazole with other anti-manic agents or placebo
48 RCTs comparing placebo with anti-manic agents
18 RCTs comparing lithium with other anti-manic agents or placebo
13 RCTs comparing haloperidol with other anti-manic agents or placebo
7 RCTs comparing quetiapine with other anti-manic agents or placebo
6 RCTs comparing ziprasidone with other anti-manic agents or placebo
17 RCTs comparing olanzapine with other anti-manic agents or placebo
3 RCTs comparing lamotrigine with other anti-manic agents or placebo
10 RCTs comparing valproate with other anti-manic agents or placebo
10 RCTs comparing risperidone with other anti-manic agents or placebo
2 RCTs comparing asenapine with other anti-manic agents or placebo
8 RCTs comparing carbamazepine with other anti-manic agents or placebo
5 RCTs comparing topiramate with other anti-manic agents or placebo
1 RCT comparing gabapentin with other anti-manic agents or placebo
582 records screened after duplicates removed
188 full-text articles assessed for eligibility
9 additional unpublished studies after  contact with pharmaceuticial 
industries manufacturing antimanic drugs
7110 records identified through database searching
 
FIGURE 2. Included and excluded studies (PRISMA flow-diagram, www.prisma-
statement.org). 
 
Overall, 16 073 patients were randomized to one of the 14 anti-manic treatments or to 
placebo and were included in the multiple-treatments meta-analysis. 15 673 patients 
contributed to the efficacy analysis as continuous outcome (63 studies) and 15 626 to the 
acceptability analysis (65 studies). 47 studies provided data for dichotomous efficacy 
secondary outcome (12 649 participants). The mean duration of studies was 3.4 weeks 
(SD 1.1; one study lasted 2 weeks, 49 lasted 3 weeks, and 17 ranged between 4 and 6 
weeks), and the mean sample size was 105.7 patients per group (minimum–maximum 7–
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458). Supplementary unpublished information was obtained from trial investigators for 
26 of the 68 included studies (38%).  
Most of included studies recruited patients rated as having moderate to severe manic 
symptoms, and 52 trials (76%, 13 436 participants) were done in inpatient clinics (only 
two in outpatient clinics and in the remaining studies the setting was unclear). The 
overall quality of studies assessed with the Cochrane Collaboration bias tool was rated 
as good, even though some studies did not record details about randomization process 
and allocation concealment and there were only few randomized trials at low risk of bias 
in every question-based entry (Figure 3 and Appendix 4).  
 
 
 
 
 
FIGURE 3. Study quality evaluation using the Cochrane Collaboration risk of bias tool (Higgins 
et al., 2011). 
 
 
Figure 4 shows the network of eligible comparisons for primary efficacy outcome of the 
multiple-treatments meta-analysis: this pattern of comparisons is called geometry of the 
treatment network. This network’s geometry reflects the wide clinical context of the 
multiple competing treatments for acute mania. In this network many treatments are 
compared with others or with placebo. The thickness of the lines is proportional to the 
number of trials addressing each specific comparison (co-occurrence), each node 
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corresponds to a different drug under investigation (diversity) and the size of every 
node is proportional to the number of randomized participants (sample size). 
 
FIGURE 4. Network of eligible comparisons for the multiple-treatments meta-analysis for 
efficacy. The width of the lines is proportional to the number of trials comparing every pair of 
treatments, and the size of every node is proportional to the number of randomized participants 
(sample size). The networks of eligible comparisons for acceptability analysis dropout rate) and 
for efficacy as binary outcome are similar (see Appendix 5). 
 
 
Of the 91 possible pair-wise comparisons between the 14 treatments, 33 have been 
studied directly in one or more trials for efficacy as continuous outcome, 27 for efficacy 
as binary outcome, and 34 for acceptability. All anti-manic drugs had at least one 
placebo-controlled randomized trial.  Most of them were directly compared with at least 
three other drugs.  For primary outcomes, meta-analysis of the direct comparisons 
showed significant efficacy for all anti-manic treatments compared with placebo, with 
the exception of topiramate and gabapentin. In the comparisons between active drugs, 
olanzapine, lithium, and carbamazepine were more than valproate; haloperidol more 
than lithium, quetiapine, and ziprasidone; olanzapine more than asenapine; and lithium 
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more than topiramate. These results arise from 33 independent analyses without 
adjustment for multiple testing (so roughly two CIs would be expected to exclude 0 by 
chance alone). Risperidone, olanzapine, and quetiapine had fewer dropouts than did 
placebo, and placebo fewer than did topiramate. Haloperidol had fewer 
discontinuations than did quetiapine; quetiapine than lithium; and olanzapine than 
risperidone and asenapine.  
 
Overall, statistical heterogeneity was moderate, although for most comparisons 95% CIs 
were wide and included values indicating very high or no heterogeneity, which 
portrayed the small number of studies available for every pair-wise comparison (see 
Appendix 6). In the meta-analyses of direct comparisons for efficacy, I² values higher 
than 75% were recorded for the comparisons ziprasidone versus placebo (I²=76.6%) and 
olanzapine versus lithium (I²=89.2%), with five and three studies, respectively. For 
acceptability, I² values higher than 75% were recorded for the comparisons aripiprazole 
versus haloperidol (I²=84.1%) and lithium versus lamotrigine (I²=82.0%), with two and 
three studies in the meta-analysis, respectively.  
 
Haloperidol, risperidone, olanzapine, lithium, quetiapine, aripiprazole, carbamazepine, 
asenapine, valproate, and ziprasidone were significantly more effective than placebo, 
while gabapentin, lamotrigine, and topiramate were not. For drop-outs, olanzapine, 
risperidone, and quetiapine were significantly better than placebo (Figure 5 and 
Appendix 7). 
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FIGURE 5. Forest plots of MTM results for efficacy outcomes and dropout rate with placebo as reference 
compound. Standardised mean differences lower than 0 and ORs lower than 1 favour active compound. *As 
stated in the protocol, data from risperidone and paliperidone were merged. MTM= multiple-treatments 
meta-analysis. OR=odds ratio. CrI=credibilty interval. 
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On the secondary dichotomous outcome for efficacy, the results were consistent with 
continuous outcome, but less clear cut and with wider CIs. Asenapine, ziprasidone, 
lamotrigine, and topiramate were not significantly more effective than placebo and no 
binary efficacy data were available for gabapentin (Figure 5). The few data made it 
difficult to draw clear conclusions for this outcome. In head-to-head comparisons, 
haloperidol had the highest number of significant differences compared with other anti-
manic drugs, partly because it was often used as an active comparator (Figure 6).  
Haloperidol was significantly more effective than lithium, quetiapine, aripiprazole, 
carbamazepine, asenapine, valproate, ziprasidone, lamotrigine, topiramate, and 
gabapentin.  Risperidone and olanzapine had a very similar profile of comparative 
efficacy, being more effective than valproate, ziprasidone, lamotrigine, topiramate, and 
gabapentin. Topiramate and gabapentin were significantly less effective than all the 
other anti-manic drugs. In terms of dropout rate, haloperidol was significantly inferior 
to olanzapine; lithium inferior to olanzapine, risperidone, and quetiapine; lamotrigine 
inferior to olanzapine and risperidone; gabapentin inferior to olanzapine; topiramate 
inferior to many other anti-manic treatments, such as haloperidol, olanzapine, 
risperidone, quetiapine, aripiprazole, carbamazepine, and valproate (Figure 6).  
Most loops (networks of three comparisons that arise when collating studies involving 
different selections of competing treatments) were consistent, since their 95% CIs 
included 0 (ie, the direct estimate of the summary effect does not differentiate from the 
indirect estimate) according to the forest plots. Analysis of inconsistency indicated that 
there was inconsistency in three of the total 33 loops for efficacy measured as a 
continuous outcome (aripiprazole-placebo-haloperidol; olanzapine-placebo-risperidone; 
quetiapine-placebo-haloperidol), but none for acceptability (34 loops) or binary efficacy 
(18 loops) (for full details see Appendix 8). 
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We could not identify any important variables that differed across comparison 
in those loops, but the number of included studies was very small in the three 
inconsistent loops. Exclusion of the studies adopting strategies for combination 
or augmentation treatment resulted in a total of 48 trials. The MTM model was 
We could not identify any important variables that differed across comparison 
in those loops, but the number of included studies was very small in the three 
inconsistent loops. Exclusion of the studies adopting strategies for combination 
or augmentation treatment resulted in a total of 48 trials. The MTM model was 
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refitted accordingly and no material change in either the groups of estimated SMDs or 
ORs was recorded. The secondary analysis including risperidone and paliperidone as 
separate drugs did not produce materially different results. In this secondary analysis, 
some modest differences might be expected to arise by chance alone, but we noted that 
the joint effect of risperidone and paliperidone was mainly due to the effectiveness of 
risperidone rather than paliperidone. Figure 7 presents all anti-manic drugs ordered by 
their overall probability to be the best treatment in terms of both efficacy and 
acceptability, showing the separate contributions to the overall scores of efficacy and 
acceptability.  
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FIGURE 7. Drugs ordered by overall probability to be the best treatment in terms of both efficacy 
(blue) and acceptability (red), showing the separate contributions to the overall scores of efficacy 
and acceptability. 
 
Haloperidol, risperidone, and olanzapine were among the most effective treatments, and 
olanzapine, risperidone, and quetiapine were better than the other drugs in terms of 
acceptability. We ranked anti-manic drugs according to these two dimensions (Figure 8). 
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FIGURE 8. Ranking of anti-manic agents according to primary outcomes. 
 
 
The common heterogeneity SD was 0.14 (95% CrI 0.09–0.21) for the efficacy SMD and 
0.37 (95% CrI 0.26–0.50) for the OR for dropout. After the meta-regression analysis, the 
SMDs, Ors and the final rankings did not change appreciably. For full details on 
analyses, see Appendices 9 and 10. For efficacy we showed that overall sponsorship 
slightly favoured investigational drugs over placebo although only asenapine lost 
evidence of significant superiority to placebo after adjustment (see Appendix 11).  
The three best treatments in terms of acceptability (risperidone, olanzapine, and 
quetiapine) and valproate scored better after adjustment for sponsorship. 
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DISCUSSION 
 
This MTM is the first analysis that incorporates direct and indirect comparisons between 
pharmacological treatments for acute mania. Study results show both statistically and 
clinically significant differences between drugs for the treatment of acute mania. 
Haloperidol, risperidone, and olanzapine were better than other drugs for efficacy 
profile. In terms of tolerability, olanzapine, risperidone, and quetiapine were better than 
haloperidol. Antipsychotic drugs were, overall, significantly more effective than mood 
stabilisers. Of the antipsychotic drugs, the two treatments likely to be ranked as superior 
for efficacy and acceptability were risperidone and olanzapine.  
Other antipsychotics (asenapine and ziprasidone), valproate, and lithium showed 
generally inferior efficacy and acceptability profiles, making them less obvious initial 
choices for prescription of pharmacological treatment of acute mania. Lamotrigine, 
topiramate, and gabapentin were not significantly better than placebo in terms of 
efficacy, so there seems to be no reason to use them in the treatment of mania. With the 
large number of treatment options, meta-analyses of direct comparisons are inevitably 
limited by the relatively small number of studies that assessed a particular pair of 
treatments. Multiple-treatments meta-analysis reduces this issue by creating indirect 
comparisons and allowing data synthesis that can help identify the most effective 
treatment. Nonetheless, we found no usable data for chlorpromazine, a first-generation 
antipsychotic drug that is still frequently used in clinical practice. Less recent studies did 
not provide outcome data, so new studies are needed to assess the efficacy and 
acceptability of such an important compound.  
Our study has several strengths. The review methods were systematic and 
comprehensive, retrieving a significant amount of unpublished evidence. We applied a 
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mixed model, which is thought to be the most appropriate method for multiple-
treatments meta-analysis. Although our pooled estimates were with a particular degree 
of heterogeneity, the random effect approach took into account variations at the study 
level. Our results show that some medicines are beneficial for acute mania, although 
effect sizes for most treatments versus placebo were modest. We also assessed the role of 
sponsorship in influencing trials results. We found that the efficacy estimates for most 
drugs were slightly higher in trials done by the drug manufacturer, although the results 
of this sensitivity analysis are inconsistent, suggesting that manufacturers’ trials could 
even underestimate acceptability. Extrapolation of data from mania trials to ordinary 
practice should be done with caution. The trials were invariably short term, most as 
short as 3 weeks. Furthermore, because only patients who were less severely affected 
could provide informed consent, those with more severe disease were excluded. 
Discontinuation of drug treatment also provides a crude composite measure of 
acceptability. We did not directly investigate specific side-effects, toxic effects, personal 
or social functioning, or quality of life, which limits the confidence with which we can 
say that risperidone and olanzapine have the most favourable balance between benefits 
and acceptability. We based this statement on rates of dropout rather than direct 
measures of patient’s experience. 
The best treatment in terms of efficacy alone was haloperidol, although it was of low 
acceptability. Moreover, despite the increasing number of randomized trials assessing 
drugs for mania in recent years, the total number of studies and patients randomly 
assigned is still low compared with disorders such as schizophrenia or depressive 
disorder. This low number might indicate specific difficulties associated with doing 
randomized trials in acute mania, which may go beyond the difficulties generally 
inherent in psychopharmacological drug trials because of the excited mental state of 
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participants. All statements comparing the merits of one medicine with another must be 
tempered by the potential biases and uncertainties that result from choice of dose and 
choice of patients.  
The selected dose is an important tolerability issue for haloperidol because, in the past, 
high doses of haloperidol (up to 30 mg daily) were routinely used for manic patients: the 
incidence of extra-pyramidal side-effects was common and generally accepted as a cost 
of treatment. In the included trials, doses were generally lower than the high doses used 
in the past so our findings broadly apply to doses of haloperidol of about 10 mg per day. 
However, the lowest dose that is effective for haloperidol has not been reliably 
established. The use of doses of haloperidol of around 10 mg might still favour 
comparators, because extra-pyramidal side-effects are seen early in treatment even at 
this dose. Moreover, other adverse effects associated with newer antipsychotic drugs, 
such as weight gain and metabolic effects, will probably not contribute to early 
discontinuations to the same extent as the extra-pyramidal side-effects. Haloperidol is 
one of the oldest available anti-manic drugs and is still frequently used worldwide as 
standard treatment for mania, notwithstanding the known risk of inducing extra-
pyramidal symptoms and, possibly, depression. The choice of patients for trials will 
have been influenced by eligibility related to previous exposure to or intolerance of trial 
treatment options. This fact will obviously have some effect on trials comparing an old 
drug such as haloperidol with a new option. More generally, to enter manic patients into 
randomized trials is difficult, so those who are entered might not be fully representative 
of those who cannot be.  
Our results apply only to the acute manic phase of bipolar disorder (3-week treatment) 
and do not inform the clinically important issue of which pharmacological treatments 
best prevent relapse and stabilize mood in the medium and long term. Drugs that are 
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most effective in the acute phase might not be the best choice for long term treatment. 
An analysis done with the methods of mixed treatment comparison showed stronger 
evidence for lithium as first-line maintenance treatment of bipolar disorder and possibly 
also for lamotrigine and valproate. This conclusion must be made cautiously, however, 
since few maintenance studies for bipolar disorder have been done so far.  
Nonetheless, our findings suggest the use of antipsychotics to treat the acute manic 
phase and mood stabilizers, possibly in combination and particularly with lithium, for 
long-term treatment. Results from this study emphasize the need for new treatment to 
show either greater efficacy or acceptability than the existing best standard treatments 
and serve as a disincentive to the development of drugs that offer little to patients other 
than increased costs. 
Application of our results should take into account any limitations of the analysis and 
the specific clinical situation. We have to consider that the geometry of a network is only 
a snapshot of the status quo at the time when meta-analysis is conducted. A network 
may evolve over time as more trials involving more or different treatments are 
conducted. In all cases, it is important to study the evolving geometry of the network. 
This would help determine whether the evolution of the research agenda is justified 
scientifically or is driven by selective preferences based on nonscientific reasons. 
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METHODS 
 
Study selection, patients’ characteristics and data collection 
 
We identified all randomized, double-blind trials comparing one active anti-manic drug 
at a therapeutic dose (first or second generation antipsychotics and the so-called mood 
stabilizers) with another active anti-manic drug or with placebo as oral therapy in the 
treatment of adults with acute mania. Combination studies (when combining drugs of 
the same class, for instance antipsychotic plus antipsychotic) and augmentation studies 
(when combining drugs belonging to different classes, for instance antipsychotic plus 
mood stabilizer) were also included. The participants were both males and females or, 
aged 18 years or older and with a primary diagnosis of bipolar I disorder (manic or 
mixed episode) according to standardized diagnostic criteria. Both fixed-dose and 
flexible-dose designs were allowed. Only studies recruiting participants with a serious 
concomitant medical illness as an inclusion criterion were excluded. 
 
We searched EMBASE (1980 to 2010 Week 44), Ovid MEDLINE(R) In-Process & Other 
Non-Indexed Citations and Ovid MEDLINE(R) (1950 to Present), PsycINFO (1806 to 
November Week 3 2010), CINAHL (up to November 25th 2010), and the Cochrane 
Central Register of Controlled Trials (CENTRAL) (up to November 25th 2010). 1 
We also searched the trial databases of the US Food and Drug Administration, the UK 
Medicines and Healthcare products  Regulatory Agency, the European Medicines 
Agency, the Australian Therapeutic Goods Administration. Trial registers 
                                                     
1 The Cochrane Central Register of Controlled Trials (CENTRAL) serves as the most comprehensive source 
of reports of controlled trials. CENTRAL is published as part of The Cochrane Library and is updated 
quarterly. As of January 2008 (Issue 1, 2008), CENTRAL contains nearly 530,000 citations to reports of trials 
and other studies potentially eligible for inclusion in Cochrane reviews, of which 310,000 trial reports are 
from MEDLINE, 50,000 additional trial reports are from EMBASE and the remaining 170,000 are from other 
sources such as other databases and hand-searching. 
 Many of the records in CENTRAL have been identified through systematic searches of MEDLINE and 
EMBASE. CENTRAL, however, includes citations to reports of controlled trials that are not indexed in 
MEDLINE, EMBASE or other bibliographic databases; citations published in many languages; and citations 
that are available only in conference proceedings or other sources that are difficult to access. It also includes 
records from trials registers and trials results registers (full details available at http://www.cochrane-
handbook.org/). 
 CENTRAL is available free of charge to all CRGs through access to The Cochrane Library. The web address 
for The Cochrane Library is: http://www.thecochranelibrary.com. 
 
 44 
 
(ClinicalTrials.gov in the USA, ISRCTN and National Research Register in the UK, 
Netherlands Trial Register in the Netherlands, EUDRACT in the EU and the Australian 
Clinical Trials Registry in Australia) and websites of pharmacological industries were 
hand-searched for published, unpublished and ongoing RCTs.  
No language restrictions were applied.  
Electronic databases were searched using the following strategy: [bipolar disorder or 
bipolar depression or mania or manic or hypomania or cyclothymic cycle or ultra-rapid cycling or 
ultradian cycling or RCBD or DMX or mixed depression or mixed bipolar or reactive depression 
or psychogenic depression or puerperal psychosis or puerperium psychosis or excited psychosis] 
and combined with a list of antipsychotics, including [(amisulpride or aripiprazole or benperidol 
or chlorpromazine or chlorprothixene or clozapine or flupentixol or fluspirilene or haloperidol or 
levomepromazine or olanzapine or paliperidone or pericyazine or perphenazine or pimozide or 
prochlorperazine or promazine or quetiapine or risperidone or sertindole or sulpiride or 
trifluoperazine or zotepine) or mood stablisers, including (alprazolam or bromazepam or 
carbamazepine or chlordiazepoxide or clobazam or clonazepam or clorazepate or delorazepam or 
diazepam or ethosuximide or flunitrazepam or flurazepam or flutoprazepam or gabapentin or 
lacosamide or lamotrigine or levetiracetam or lithium or loprazolam or lorazepam or 
lormetazepam or mexazolam or midazolam or nitrazepam or oxazepam or oxcarbazepine or 
phenobarbital or phenytoin or prazepam or pregabalin or temazepam or tiagabine or topiramate or 
valproic acid or verapamil or vigabatrin or zonisamide)]. 
MEDLINE – OVID SP interface 
□ Population group 
exp affective disorders, psychotic/  
((bipolar or bi?polar or bi polar) adj5 (disorder$ or depress$)).tw.  
(mania$ or manic$ or hypomania$).tw.  
(((cyclothymi$ or rapid or ultradian) adj5 cycl$) or RCBD).tw.  
(dmx$1 or (mixed adj3 (depress$ or bipolar or bi polar))).tw.  
((reactive or psychogenic) and depress$).mp.  
exp psychotic disorders/ and exp puerperal disorders/  
((puerperal or post partum or postpartum or puerperium) adj3 psychos$).tw.  
(excit$ and (psychos$ or psychotic$)).tw.  
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□ Interventions 
 
Antipsychotics 
 
exp antipsychotic agents/  
(antipsychotic$ or anti psychotic$ or (major adj2 (butyrophenon$ or phenothiazin$ or 
tranquil$)) or neuroleptic$).tw. 
(amisulprid$ or aminosultoprid$ or amisulpirid$ or dan 2163 or dan2163 or sertol$ or 
socian or solian).tw. 
(aripiprazol$ or abilify or abilitat ).tw. 
benperidol/ or (benperidol$ or anquil or benperidon$ or benzoperidol$ or benzperidol$ 
or frenactil$ or frenactyl or glianimon$ or phenactil$).tw. 
chlorpromazine/ or (chlorpromazin$ or aminazin$ or chlorazin$ or chlordelazin$ or 
contomin$ or fenactil$ or largactil$ or propaphenin$ or thorazin$).tw. 
chlorprothixene/ or (chlorprothixen$ or aminasin$ or aminasin$ or aminazin$ or 
aminazin$ or ampliactil$ or amplictil$ or ancholactil$ or chlopromazin$ or chlor pz or 
chlorbromasin$ or chlordelazin$ or chlorderazin$ or chloropromazin$ or chlorpromanyl 
or chlorpromazin$ or chlorprotixen$ or clordelazin$ or clorpromazin$ or contomin$ or 
elmarin$ or fenactil$ or hibanil$ or hibernal$ or hiberno$l or klorpromex or largactil$ or 
largactyl or megaphen$ or neurazin$ or novomazin$ or phenathyl or plegomazin$ or 
plegomazin$ or proma or promacid$ or promactil$ or promapar or promazil$ or 
propaphen$ or propaphenin$ or prozil or psychozin$ or sanopron$ or solidon$ or 
sonazin$ or taractan$ or taroctil$ or thor prom or thorazen$ or thorazin$ or torazin$ or 
vegetamin a or vegetamin b or wintamin$ or wintermin$ or zuledin$).tw. 
clozapine/ or (clozapin$ or alemoxan$ or azaleptin$ or clozari$1 or dorval or dozapin$ 
or fazaclo or lapenax or leponex or wander compound).tw. 
flupenthixol/ or (flupentixol$ or flupenthixol$ or depixol$ or emergil$ or fluanxol$ or 
flupentixol$ or emergil$ or fluanxol$ or piperazineethanol$ or viscoleo).tw. 
fluspirilene/ or (fluspirilen$ or fluspi or imap or kivat or redeptin$ or 
spirodiflamin$).tw. 
haloperidol/ or (haloperidol$ or aloperidin$ or celenase or cerenace or fortunan$ or 
haldol or halidol or haloneural$ or haloperitol$ or halosten or keselan or linton or  
serenace or serenase or siegoperidol$ or sigaperidol$).tw. 
methotrimeprazine/ or (levomepromazin$ or 2 methoxytrimeprazin$ or hirnamin$ or 
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levo promazin$ or levomeprazin$ or levopromazin$ or levoprom$ or mepromazin$ or 
methotrimeprazin$ or methotrimperazin$ or milezin$ or minozinan$ or neozin$ or 
neuractil$ or neurocil$ or nirvan or nozinan$ or sinogan or tisercin$ or tizercin$ or 
tizertsin$ or veractil$).tw. 
(olanzapin$ or lanzac or midax or olansek or zydis or zyprex$).tw. 
(paliperidon$ or 9 hydroxyrisperidon$ or invega).tw. 
(pericyazin$ or aolept or neulactil$ or neuleptil$ or periciazin$ or properciazin$ or 
propericiazin$).tw. 
perphenazine/ or (perphenazin$ or chlorperphenazin$ or chlorpiprazin$ or 
chlorpiprozin$ or decentan$ or etaperazin$ or ethaperazin$ or fentazin$ or perfenazin$ 
or perfenazin$ or perferazin$ or perphenan$ or perphenezin$ or thilatazin$ or 
tranquisan$ or trifalon$ or trilafan$ or trilafon$ or trilifan$ or triliphan$).tw. 
pimozide/ or (pimozid$ or antalon$ or opiran$ or orap or pimocid$ or pimorid$ or 
pinozid$).tw. 
prochlorperazine/ or (prochlorperazin$ or capazin$ or chlormeprazin$ or chlorpeazin$ 
or chlorperazin$ or compazin$ or dicopal$ or emelent or kronocin$ or meterazin$ or 
metherazin$ or nipodal$ or prochlor perazin$ or prochlorpemazin$ or prochlorperacin$ 
or prochlorperzin$ or prochlorpromazin$ or proclorperazin$ or tementil$ or 
temetil$).tw. 
promazine/ or (promazin$ or alofen$ or alophen$ or ampazin$ or amprazim$ or 
centractyl or delazin$ or esparin$ or lete or liranol$ or neo hibernex or neuroplegil$ or 
piarin$ or prazin$ or pro tan or promantin$ or promanyl$ or promilen$ or promwill or 
protactil$ or protactyl$ or romthiazin$ or romtiazin$ or sediston$ or sinophenin$ or 
sparin$ or tomil or varophen$ or verophen$).tw. 
(quetiapin$ or seroquel or tienapin$).tw. 
risperidone/ or (risperidon$ or belivon$ or risolept or risperdal$).tw. 
(sertindol$ or indole or serdolect or serlect).tw. 
sulpiride/ or (sulpirid$ or abilit or aiglonyl$ or arminol$ or deponerton$ or desisulpid$ 
or digton or dobren or dogmatil$ or dogmatyl or dolmatil$ or eglonyl or ekilid or 
equilid or guastil$ or isnamid$ or leboprid$ or levopraid or levosulpirid$ or meresa or 
mirado$l or neogama or pontirid$ or psicocen$ or sulfirid$ or sulp$1 or sulperid$ or 
sulpitil$ or sulpivert or sulpor or sulpyride or synedil$ or tepavil$ or vertigo meresa or 
vertigo neogama or vipral).tw. 
trifluoperazine/ or (trifluoperazin$ or apotrifluoperazine$ or calmazin$ or 
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dihydrochlorid$ or eskazin$ or eskazin$ or eskazinyl or fluoperazin$ or flupazin$ or 
jatroneural$ or modalina or stelazin$ or terfluzin$ or terfluzin$ or trifluoperazid$ or 
trifluoperazin$ or trifluoperzin$ or trifluoroperazin$ or trifluorperacin$ or trifluperazin$ 
or triflurin$ or triftazin$ or triftazinum or triphtazin$ or triphthasin$ or triphthazin$).tw. 
(zotepin$ or lodopin$ or nipolept).tw. 
clopenthixol/ or (zuclopenthixol$ or acuphase or clopenthixol$ or clopixol or 
cisordinol$ or sedanxol$).tw. 
 
Benzodiazepines 
 
exp benzodiazepines/ 
(benzo$1 or benzodiazepin$).tw. 
alprazolam/ or (alprazolam or alprox or apo alpraz or apoalpraz or aprazolam$ or 
cassadan$ or constan$2 or esparon$ or helex or kalma or novo alprazol$ or 
novoalprazol$ or nu alpraz or nualpraz or ralozam or solanax or tafil$1 or trankimazin$ 
or valeans or xanax or xanor).tw. 
bromazepam/ or (bromazepam or anxyrex or bartul or bromalich or bromazanil$ or 
bromazep von ct or durazanil$ or lectopam$ or lexamil$ or lexatin$ or lexaurin$ or 
lexilium or lexomil$ or lexotan$ or lexotanil$ or lexotanil$ or normoc or sintrogel$).tw. 
chlordiazepoxide/ or (chlordiazepoxid$ or methaminodiazepoxid$ or elenium$ or 
librium$ or chlozepid$ or ansiacal$ or a poxide or benzodiapin$ or cebrum$1 or 
chlordiazepoxyd$ or chlorodiazepoxid$ or clopoxid$ or contol$ or decacil$ or defobin$ 
or disarim$ or dizepin$ or dopoxid$ or droxol$ or eden psich or elenium$ or elenum$ or 
equibral$ or kalmocaps or labican$ or librelease or libritabs or librium or lipoxide or 
mesural$ or metaminodiazepoxid$ or methaminodiazepoxid$ or mildmen$ or mitran$ 
or multum$ or murcil$ or napoton$ or napoton$ or novosed$ or psichial$ or psicosan$ 
or psicoterin$ or radepur or reliberan$ or reposans 10 or risolid or seren vita or servium 
or silibrin$ or sk lygen or sonimen$ or timosin$ or viansin$ or viopsicol$).tw. 
(clobazam or chlorepin$ or clobazepam or clorepin$ or frisium or noiafren$ or urbadan$ 
or urbanil$ or urbanyl).tw. 
clonazepam/ or (clonazepam or antelepsin$ or clonopin$ or iktorivil$ or klonazepam or 
klonopin$ or landsen$ or rivotril$).tw. 
clorazepate dipotassium/ or (clorazepat$ or carboxylic acid or chlorazepat$ or 
chloroazepat$ or clorazepic acid or tranxen$ or tranxilium).tw. 
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(delorazepam or briantum$ or chlordemethyldiazepam or chlordesmethyldiazepam or 
chloro n demethyldiazepam or chlorodemethyldiazepam or chlorodesmethyldiazepam 
or  
chloronordiazepam or (diazepam adj2 chloro$)).tw. 
diazepam/ or (diazepam or alupram or ansiolin$ or antenex or apaurin$ or apaurin$ or 
apozepam or assiva$l or audium$ or bialzepam or bialzepan$ or calmpos$ or cercin$ or 
cercin$ or cersin$ or chlordiazepam or diastat or diazelium or diazemuls or diazidem or 
ducen$ or duxen$ or eridan or eurosan$ or evacalm$ or fanstan$ or faustan$ or faustan$ 
or gewacalm$ or lamra or lembrol$ or lipodiazepam or lorinon$ or methyldiazepinon$ 
or methyldiazepinon$ or morosan$ or neocalm$ or neurolytril$ or noan or novazam or 
paceum or plidan or psychopax or relanium or sedapam or seduxen$ or serendin$ or 
setonil$ or sibazon$ or sonacon$ or stesolid$ or stesolin$ or tanquo tablinen$ or 
tranimul$ or tranquo puren or umbrium$ or valaxon$ or valiquid$ or valium or valpam 
or valreleas$ or vatran$ or vival$ or vivol4 or zetran$).tw. 
flunitrazepam/ or (flunitrazepam or flurazepam or fluridrazepam or darkene or 
flunibeta or flunimerck or fluninoc or flunipam or flunita or flunitrax or flunizep von ct 
or hypnodorm$ or hypnosedon$ or inervon$ or narcozep or parnox or rohipnol$ or 
rohypnol$ or roipnol$ or silece or valsera).tw. 
flurazepam/ or (flurazepam or benozil$ or dalmadorm$ or dalman$ or dalmate or 
dormodor$ or lunipax or staurodorm$ or dalman$ or dormodor$ or dalmadorm$).tw. 
(flutoprazepam or restas).tw. 
loprazolam.tw. 
lorazepam/ or (lorazepam or almazin$ or alzapam or apolorazepam or ativan or 
bonatranquan$ or donix or duralozam or durazolam or idalprem or kendol$ or laubeel 
or lorabenz or loranas$ or loranaz$ or lorans or lorax or lorazep von ct or loridem$ or 
lorivan$ or mesmerin$ or novo lorazem$ or novolorazem$ or novo lorazem$ or nu loraz 
or nuloraz or orfidal or orifadal$ or pro dorm or quait or securit or sedicepan$ or 
sinestron$ or somagerol$ or tavor or temesta or tolid wypax).tw. 
(lormetazepam or loramet or (lorazepam adj2 methyl) or methyllorazepam or minians or 
minias or noctamid$ or pronoctan$).tw. 
(mexazolam or melex or sedoxil$).tw. 
midazolam/ or (midazolam or dormicum or dormonid$ or hypnova$l or hypnovel$ or 
hypnoyvel$ or versed).tw. 
nitrazepam/ or (nitrazepam or alodorm or atempol$ or benzalin$ or dormalon$ or 
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dormo puren or dumolid or eatan or eunoctin$ or hypnotex or imadorm or imeson$ or 
insomin$ or mogadan$ or mogadon$ or nelbon$ or nirven$ or nitra zepam or nitrados or 
nitravet or nitrazadon$ or nitrazep or nitrodiazepam or novanox or pacisyn or 
radedorm$ or remnos or restorem$ or sedamon$ or serenade or somnased$ or somnibel$ 
or somnit$).tw. 
oxazepam/ or (oxazepam or abboxapam or adumbran$ or alopam or anxiolit$ or 
azutranquil$ or durazepam or expidet$ or hilong or isodin$ or linbial$ or noctazepam or 
oxapuren$ or oxepam or praxiten$ or serax or serenid$ or serepax or seresta or serpax or 
sigacalm$ or sobril$ or tazepam$ or uskan).tw. 
prazepam/ or (prazepam or centrax or demetrin$ or lysanxia or mono demetrin$ or 
monodemetrin$ or reapam or sedapran$ or verstran).tw. 
temazepam/ or (temazepam or apo-temazepam or dasuen or euhypnos or 
hydroxydiazepam or levanxol$ or methyloxazepam or nocturne$ or norkotral tema or 
normison$ or normitab or nortem or oxydiazepam or planum or pronervon t or 
remestan$ or restoril$ or signopam or temaz$1 or temazep von ct or temazepax or 
temtabs or tenox or texapam).tw.  
 
Anticonvulsants 
 
exp anticonvulsants/ or antimanic agents/ or tranquilizing agents/ 
((mood adj2 stabili$) or ((antimanic or anti manic) adj2 (agent$ or drug$ or stabil$)) or 
anticonvuls$ or anti convuls$ or tranquil?li?er$ or tranquil?i?ing).tw. 
carbamazepine/ or (carbamazepin$ or amizepin$ or amizepin$ or amizepin$ or atretol 
or biston or calepsin$ or carbategral$ or carbatrol$ or carbazepin$ or convulin$ or 
epimax or epitol or equetro or finlepsin$ or finlepsin$ or lexin or mazepin$ or neurotol 
or neurotop or servimazepin$ or sirtal or tegral or tegretal or tegretol or tegrital or 
telesmin or teril or timonil).tw. 
ethosuximide/ or (ethosuximid$ or asamid$ or emesid$ or ethosuccimid$ or 
ethosuccinimid$ or ethylmethylsuccimid$ or ethylsuximid$ or ethymal$ or etosuximid$ 
or mesentol$ or pemal or petinimid$ or petnidan$ or petnidan$ or pyknolepsin$ or 
ronton$ or simatin$ or succinutin$ or sucsilep or suxilep or suxinutin$ or zarontin$ or 
zarontin$).tw. 
(gabapentin$ or neurontin$ or neurotonin$).tw. 
(lacosamid$ or erlosamid$ or harkoserid$ or n acetyl o methyl dextro serine 
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benzylamid$).tw. 
(lamotrigin$ or labileno or lamictal).tw. 
(levetiracetam or etirazetam or etiracetam or keppra).tw. 
lithium$.sh. or (lithium$ or camcolit or candamid$ or carbolith or carbolitium or cibalith 
s or contemnol$ or dilithium or eskalith or hypnorex or li salt or limas or linthane or 
liskonium or liskonum or litarex or lithane or lithiofor or lithionit or lithiophor or 
lithobid or lithocarb or lithonate or lithotabs or maniprex or mesin or micalith or 
neurolepsin or neurolithium or plenur or priadel or quilinormretard or quilonorm or 
quilonum or teralithe or theralite or theralithe lp).tw. 
(oxcarbazepin$ or apydan$ or oxocarbazepin$ or timox trileptal$).tw. 
exp phenobarbital/ or (phenobarbit$ or adonal$ or aephenal$ or agrypnal$ or alepsal$ 
or amylofen$ or aphenylbarbit$ or aphenyletten$ or austrominal$ or barbapil$ or 
barbellen$ or barbenyl or barbiletta$ or barbilixir or barbinal$ or barbiphen$ or 
barbiphenyl or barbivis or barbonal$ or barbonalett or barbophen$ or bardorm or bartol 
or bialminal$ or calmette$ or calminal$ or carbronal$ or cardinal$ or cemalonal$ or 
codibarbital$ or coronaletta or cratecil$ or damoral$ or dezibarbitur or dormina or 
dormiral$ or dromural$ or ensobarb or ensodorm or epanal$ or epidorm or epilol$ or 
episedal$ or epsilon$ or eskabarb or etilfen$ or euneryl or fenbital$ or fenemal$ or 
fenobarbital$ or fenolbarbital$ or fenosed or fenyletta$ or gardenal$ or gardepanyl or 
glysoletten$ or haplopan$ or haplos or helional$ or hennoletten$ or hypnaletten$ or 
hypno tablinetten$ or hypnogen fragner or hypnolon$ or hypnotal$ or hysteps or lefebar 
or leonal$ or lephebar or lepinal$ or linasen$ or liquital$ or lixophen$ or lubergal$ or 
lubrokal$ or lumesette$ or lumesyn$ or luminal$ or lumofridetten$ or luphenil$ or 
luramin$ or molinal$ or neurobarb or nirvonal$ or noptil$ or nova pheno or nunol or 
parkotal$ or pharmetten$ or phen bar or phenaemal$ or phenemal$ or phenethylbarbit$ 
sodium or phenobalor phenobarb or phenobarbyl$ or phenonyl$ or phenoturic or 
phenoyl$ or phenyl ethyl barbituric acid or phenylbarbit$ or phenylethyl barbituric acid 
or phenylethylbarbituric acid or phenylethylbarbituric acid or phenylethylmalonyl urea 
or phenylethylmalonylurea or phenyletten$ or phenyral$ or polcominal$ or 
promptonal$ or seda tablinen$ or sedabar or sedicat$ or sedizorin$ or sedlyn or 
sedofen$ or sedonal$ or sedonette$ or seneval$ or sevenal$ or sombutol$ mcclung or 
somnolen$ or somnoletten$ or somnosan$ or somonal$ or spasepilin$ or starifen$ or 
stariletta$ or stental$ or teolaxin$ or theolaxin$ or triabarb or tridezibarbitur or 
versomnal$ or wakobital$ or zadoletten$ or zadonal$).tw. 
 51 
 
phenytoin/ or (phenytoin$ or aleviatin$ or antilepsin$ or antisacer or antisacer or 
cansoin$ or citrullamon$ or comital$ or danten$ or dantoin$ or denyl or di hydan$ or 
difenin$ or difetoin$ or differenin$ or difhydan$ or dihydan$ or dilantin$ or dintoin$ or 
diphantoin$ or diphedal$ or diphedan$ or diphenin$ or diphenytoin$ or ekko or 
epamin$ or epanutin$ or epelin$ or epilantin$ or eptal$ or eptoin$ or fenantoin$ or 
fenitoin$ or fenytoin$ or fenytoin$ or hidantal$ or hydantin$ or hydantoinal$ or 
hydantol$ or idantoin$ or lepitoin$ or lepsin$ or minetoin$ or neosidantoin$ or 
phenhydan$ or phenybin$ or phenydan$ or phenytonium or sanepil$ or sodantoin$ or 
sodanton or sodium diphenylhydantoinate or solantoin$ or solantyl or tacosal$ or 
zentropil$).tw. 
(pregabalin$ or 3 isobutylgaba or lyrica ).tw. 
(rufinamid$ or inovelon$ or xilep).tw. 
(tiagabin$ or gabitril$ or tiabex).tw. 
(topiramat$ or epitomax or topamax or topimax).tw. 
valproic acid/ or (valproic acid or 2 propylpentanoate or 2 propylpentanoic acid or 2 
propylpentanoic acid or 2 propylvalerate sodium or 2 propylvaleric acid or 2 
propylvaleric acid sodium or alpha propylvaler$ or apilepsin$ or convulex or 
convulsofin$ or depacon or depakene or depakin$ or depakote or deprakin$ or di n 
propylacetat$ or di n propylacetat$ sodium or di n propylacetic acid or dipropyl acetate 
or dipropyl acetic acid or dipropylacetat$ or dipropylacetatic or diprosin$ or divalproex 
or epilim or ergenyl or everiden$ or goilim or labazen$ or leptilan$ or leptilanil$ or 
mylproin$ or myproic acid or n dipropylacetic acid or orfiril or orlept or propymal$ or 
sodium 2 propylpentanoat$ or sodium 2 propylvalerat$ or sodium di n propyl acetate or 
sodium di n propylacetat$ or sodium dipropyl acetate or sodium dipropylacetate or 
sodium n dipropylacetate or valerin$ or valparin$ or valpro or valproate or vupral).tw. 
exp verapamil/ or (verapamil$ or arpamyl$ or azupamil$ or berkatens or calan or 
cardiagutt or cardibeltin$ or coer 24 or cordilox or corpamil$ or covera hs or 
dexverapamil$ or dignover or dilacoron$ or durasoptin$ or falicard or finoptin$ or 
geangin$ or ikakor or iproveratril$ or isopropylacetonitril$ or isopropylvaleronitril$ or 
isoptin$ or izoptin$ or manidon$ or novapamyl$ or phynoptin$ or securon$ or univer or 
vasolan or verabeta or veraloc or veramex or verelan or verexamil or veroptin stada or 
verpamil or vortac).tw. 
(vigabatrin$ or n vinyl 4 aminobutyric acid or n vinyl gaba or n vinyl gamma 
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aminobutyric acid or sabril or sabrilex).tw. 
(zonisamid$ or excegran or excemid or zonegran).tw.  
 
□ RCT filter - this is an adaptation of a filter designed by the Health 
Information Research Unit of the McMaster University, Ontario. 
 
exp clinical trial/ or cross over studies/ or double blind method/ or random 
allocation/ or randomized controlled trials as topic/ or single blind method/ 
(clinical adj2 trial$).tw. 
(crossover or cross over).tw. 
(((single$ or doubl$ or trebl$ or tripl$) adj5 blind$) or mask$ or dummy or 
singleblind$ or doubleblind$ or trebleblind$ or tripleblind$).tw. 
(placebo$ or random$).tw. 
(clinical trial$ or controlled clinical trial$ or random$).pt. 
  
 
□ Websites of pharmaceutical companies (last accessed on Nov 30th  2010) 
Eli Lilly: www.lilly.com 
Lundbeck: www.lundbeck.com 
Organon: www.organon.com 
Solvay: www.solvay.com 
Pfizer: www.pfizer.com 
GlaxoSmithKline: www.gsk.com 
Bristol Myers Squibb: www.mbs.com 
Wyeth: www.wyeth.com 
 
□ Medical Control Agencies (last accessed on November 30th  2010) 
Food and Drug Administration (USA): www.fda.gov 
European Medicines Agency (EU): www.emea.europa.eu 
Therapeutic Goods Administration (Australia): www.tga.gov.au 
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All relevant authors and principal manufacturers were contacted to supplement the 
incomplete report of the original papers or to provide new data for unpublished studies. 
We also checked the websites of these manufacturers for further studies. 
The Cochrane risk of bias tool was used to assess study quality.11 This instrument 
consists of six items, providing a framework for assessing the whole trial with explicit 
and transparent criteria separating facts from judgments. Two of the items (adequacy of 
sequence generation and allocation concealment) assess the strength of the 
randomization process in preventing selection bias in the assignment of participants to 
interventions; the third item (blinding) assesses the influence of performance bias on the 
study results and the fourth the likelihood of incomplete outcome data, which raise the 
possibility of bias in effect estimates. The fifth item assesses selective reporting, the 
tendency to preferentially report statistically significant outcomes (this item requires a 
comparison of published data with trial protocols, when such are available). The final 
item refers to other sources of bias that are relevant in certain circumstances, such as, for 
example, sponsorship bias. 
 
Outcome measures 
 
Acute treatment was defined as a 3-week treatment in both the efficacy and acceptability 
analyses. If 3-week data were not available, data ranging between 2 to 6 weeks were 
used (the time point given in the original study as the study endpoint was given 
preference). Mean change scores on the Young Mania Rating Scale (YMRS) and dropout 
rates (treatment discontinuation) were chosen as primary outcomes to represent 
respectively the most sensible and sensitive estimate of acute treatment efficacy and 
acceptability. If YMRS results were not available, we used the mean changes of other 
standardized rating scales for acute mania. Treatment discontinuation (acceptability) 
was defined as the number of patients who left the study early for any reason during the 
first 3 weeks of treatment, out of the total number of patients randomly assigned to each 
treatment arm. As a secondary analysis we also estimated the proportion of patients 
who responded to treatment. Response was defined as a reduction of at least 50% on the 
total score between baseline and endpoint on a standardized rating scale for mania 
(possibly YMRS; if not available, other rating scales were used).  
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 BACKGROUND  
The main aim in treating mania, hypomania and mixed episodes is to achieve rapid 
control of symptoms. This is particularly important as mania can result in disturbed 
behavior that, when extreme, can be a risk to the safety of the patient and others. Mood 
stabilizers and antipsychotic agents have long been the mainstay of treatment of acute 
mania (with and without psychotic features) (NICE, 2006; Scherk et al., 2007).  
 
Lithium and valproate are held to be effective in acute mania but their onset of action is 
slower than with antipsychotics. Prior to the introduction of the atypical antipsychotics, 
the conventional antipsychotics were the frequently used treatment for mania despite a 
relative lack of randomised controlled trials to support their use. In recent years several 
atypical antipsychotics agents have been licensed to treat mania (aripiprazole, 
olanzapine, risperidone and quetiapine). However, there is a debate about the benefits of 
newer so-called atypical antipsychotic drugs compared with older antipsychotic drugs. 
A major advantage of the atypical antipsychotics over conventional antipsychotics is the 
lower risk of extrapyramidal symptoms (EPSs) though this differential has largely been 
demonstrated in trials where the comparator was haloperidol, a high-potency 
conventional antipsychotic that is associated with a relatively high incidence of EPS. 
There is no general consensus about which of these drugs should be used first-line. 
Guidelines for the treatment of bipolar disorder vary significantly across committees or 
specialist groups (Fountoulakis et al., 2005). In particular for the treatment of acute 
mania, some guidelines recommend monotherapy with a mood stabilizer or an 
antipsychotic drug as first-line treatment, whereas others recommend a combination of a 
mood stabilizer and an antipsychotic agent.   
 
Adverse effects in short term studies tend to focus on EPS but some atypical 
antipsychotics, in particular olanzapine and clozapine, are associated with a high risk of 
significant increase in body weight and this may influence the selection even of short 
term treatments under some circumstances. 
 
The aim of this study is to compare the efficacy and acceptability of pharmacological 
treatments for acute mania, in order to inform clinical practice and mental health 
policies.  We will carry out a multiple-treatments meta-analysis (MTM). MTM is a 
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statistical technique that allows both direct and indirect comparisons to be undertaken, 
even when two of the treatments have not been directly compared (Higgins et al., 1996; 
Hasselblad et al., 1998; Lumley, 2002). Reliable information on comparative efficacy is 
essential for informing clinical practice and policymaking and MTM allows us to use all 
the available evidence to estimate  potential differences in efficacy among treatments.  
 
OBJECTIVES 
To compare individual anti-manic agents in terms of:  
 
(1) Efficacy (as continuous outcome), measured by the total score of the Young Mania 
Rating Scale (YMRS - Young et al., 1978) or another standardised rating scale, if fYMRS  
was not used. 
 
(2) Efficacy (as dichotomous outcome), measured by the total number of patients who 
had a reduction of at least 50% on the total score between baseline and endpoint on a 
standardized rating scale for mania (YMRS or another standardised rating scale, if 
YMRS was not used).  
 
(3) Acceptability of treatment, defined as the proportion of patients who left the study 
early by any cause. 
  
METHODS 
 
Criteria for considering studies for this review 
 
Types of studies 
Double-blind RCTs comparing one active drug (antipsychotic, mood stabiliser or 
benzodiazepine) with another active drug (antipsychotic, mood stabiliser or 
benzodiazepine) or placebo as oral therapy in the treatment of acute mania will be 
included. All combination studies (when combining drugs of the same class, for instance 
antipsychotic plus antipsychotic) and augmentation studies (when combining drugs 
belonging to different classes, for instance antipsychotic plus mood stabiliser) will be 
included as well. We therefore will investigate heterogeneity between these different 
types of studies. Quasi-randomized trials (such as those allocating by using alternate 
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days of the week) will be excluded. For trials which have a crossover design only results 
from the first randomisation period will be considered.  
 
Types of participants 
Patients aged 18 or older of both sexes with a primary diagnosis of acute mania or 
bipolar disorder (manic or mixed episode) according to the standardised diagnostic 
criteria used by the study authors. Most recent studies are likely to have used DSM-IV 
(APA 1994) or ICD-10 (WHO 1992) criteria. Older studies may have used ICD-9 (WHO 
1978), DSM-III (APA 1980)/DSM-III-R (APA 1987) or other diagnostic systems such as 
Feighner criteria or Research Diagnostic Criteria. There is no evidence that treatment 
effects differ depending on the diagnostic criteria used. A concurrent Axis I diagnosis of 
another psychiatric disorder will be considered as exclusion criteria. A concurrent Axis 
II diagnosis of psychiatric disorder will not be considered as exclusion criteria. Studies 
with patients with a serious concomitant medical illness as an inclusion criterion will be 
excluded.  
 
Outcome measures 
 
(1) Overall efficacy of antipsychotic treatment  
1.1 Overall efficacy will be primarily measured as the mean change of the total score 
of the YMRS from baseline to endpoint. If YMRS results are not available, we will 
use the mean change from baseline to endpoint of other standardised rating scales 
for acute mania.    
 
1.2 We will also estimate efficacy as the proportion of patients who responded to 
treatment (response is defined as a reduction of at least 50% on the total score 
between baseline and endpoint on a standardized rating scale for mania (possibly 
YMRS; if not available, other rating scales will be used). 
 
(2) Acceptability of treatment 
Treatment discontinuation (acceptability) is defined as the proportion of patients 
who left the study early for any reason, out of the total number of patients randomly 
assigned to each treatment arm. 
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Search strategy            
 
All published and unpublished randomized controlled, double-blind trials that 
compared oral doses of one of the above mentioned anti-manic drugs with another drug 
(or placebo) in the treatment of acute mania will be identified.  
We will identify relevant trials from systematic searches in the following electronic 
databases, MEDLINE, EMBASE, CINAHL, PsycINFO, and the Cochrane Central 
Register of Controlled Trials (CENTRAL). We will also consult trial databases of the 
following drug-approving agencies - (the Food and Drug Administration (FDA) in the 
USA, the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, 
the European Medicines Agency (EMEA) in the EU, the Pharmaceuticals and Medical 
Devices Agency (PMDA) in Japan, the Therapeutic Goods Administration (TGA) in 
Australia) and ongoing trial registers (clinicaltrials.gov in the USA, ISRCTN and 
National Research Register in the UK, Netherlands Trial Register in the Netherlands, 
EUDRACT in the EU, UMIN-CTR in Japan and the Australian Clinical Trials Registry in 
Australia) will be hand-searched for published, unpublished and ongoing controlled 
trials. No language restrictions will be applied. Electronic databases will be searched 
using the following strategy: [bipolar disorder or bipolar depression or mania or manic 
or hypomania or cyclothymic cycle or ultra-rapid cycling or ultradian cycling or RCBD 
or DMX or mixed depression or mixed bipolar or reactive depression or psychogenic 
depression or puerperal psychosis or puerperium psychosis or excited psychosis] and 
combined with a list of antipsychotics, including [(amisulpride or aripiprazole or 
benperidol or chlorpromazine  or chlorprothixene  or clozapine  or flupentixol  or 
fluspirilene  or haloperidol  or levomepromazine  or olanzapine  or paliperidone  or 
pericyazine or perphenazine or pimozide  or prochlorperazine  or promazine  or 
quetiapine  or risperidone or sertindole or sulpiride or trifluoperazine or zotepine) or 
mood stablisers, including (alprazolam or bromazepam or carbamazepine  or 
chlordiazepoxide  or clobazam or clonazepam or clorazepate  or delorazepam  or 
diazepam  or ethosuximide  or flunitrazepam  or flurazepam or flutoprazepam or 
gabapentin  or lacosamide  or lamotrigine  or levetiracetam  or lithium or loprazolam  or 
lorazepam  or lormetazepam  or mexazolam  or midazolam  or nitrazepam  or oxazepam 
or oxcarbazepine  or phenobarbital  or phenytoin  or prazepam or pregabalin  or 
temazepam or tiagabine  or topiramate  or valproic acid  or verapamil  or vigabatrin  or 
zonisamide)].  
 59 
 
All relevant authors and principal manufacturers will be contacted to supplement the 
incomplete report of the original papers. We will also check the websites of these 
manufacturers for further studies.  
 
 
Study selection and data extraction 
 
We will use the data that have been extracted for the previous Cochrane reviews carried 
out by the members of our review team (JG, JR, AC, GG). Concerning the update search, 
three reviewers (AC, JR and CB) will independently review references and abstracts. If 
both reviewers agree that the trial doesn’t meet eligibility criteria, we will exclude it. We 
will obtain the full text of all remaining articles and use the same eligibility criteria to 
determine which, if any, to exclude at this stage. Any disagreements will be solved via 
discussion with another member of the reviewing team (JG or GG). The same reviewers 
(AC, JR and CB) will then independently read each article, evaluate the completeness of 
the data abstraction, and confirm the quality rating. As for previous Cochrane 
systematic reviews, we will design and use a structured data abstraction form to ensure 
consistency of appraisal for each study. Information extracted will include study 
characteristics (such as lead author, publication year, journal, study setting, 
sponsorship), participant characteristics (such as diagnostic criteria, mean baseline score, 
age), intervention details (such as dose ranges, mean doses of study drugs, concomitant 
and/or rescue medications) and outcome measures (see above).  
 
 
Length of follow up 
 
In the present review, acute treatment will be defined as a 3-week treatment in all 
analyses. If 3-week data are not available, we will use data ranging between 2 and 6 
weeks (we will give preference to the time-point given in the original study as the study 
endpoint).  
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Quality Assessment  
 
To assess the quality (internal validity) of trials, we will use predefined criteria based on 
those developed by the Cochrane Collaboration. Inadequate concealment undermines 
the principle of randomization, because participants may then be allocated to a 
treatment according to prognostic variables rather than by pure chance. Therefore, two 
independent review authors (AC, JR or CB) will independently assess trial quality in 
accordance with the Cochrane Handbook (Higgins & Green, 2005). This pays particular 
attention to the adequacy of the random allocation concealment and double blinding. 
Studies will be given a quality rating of A (adequate), B (unclear), and C (inadequate) 
according to these two items. Studies which will score A or B on these criteria constitute 
the final list of included studies. Where inadequate details of allocation concealment and 
other characteristics of trials are provided, the trial authors will be contacted in order to 
obtain further information. If the raters disagree, the final rating will be made by 
consensus with the involvement (if necessary) of another member of the review group. 
 
 
Comparability of dosages 
 
We will include only studies randomizing patients to drugs within the therapeutic dose 
(both fixed-dose and flexible-dose designs will be allowed). There is the possibility that 
some trials compare one agent at the upper limit of its therapeutic range with another 
agent at the lower limit of its therapeutic range within the same study. We may look at 
heterogeneity and then add a variable (yes/no) that report if dosages are comparable 
and use this information for analysis.   
 
STATISTICAL ANALYSIS 
 
The efficacy outcome of this review will be the change of the total score of the YMRS. 
Dichotomous outcomes will be analysed on an intention-to-treat (ITT) basis: drop-outs 
will always be included in this analysis. When data on drop-outs are carried forward 
and included in the evaluation (Last Observation Carried Forward, LOCF), they will be 
analysed according to the primary studies.   
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Synthesis of results 
We will generate descriptive statistics for trial and study population characteristics 
across all eligible trials, describing the types of comparisons and some important 
variables, either clinical or methodological (such as year of publication, age, severity of 
illness, sponsorship).  
For each pair-wise comparison between anti-manic drugs, the standardized mean 
difference Hedges’s adjusted g (SMD) will be calculated as the effect size for continuous 
outcomes and the odds ratio will be calculated for dichotomous outcomes, both with a 
95% CI. We will first perform pair-wise meta-analyses by synthesizing studies that 
compare the same interventions using a random effects model (DerSimonian & Laird, 
1986) to incorporate the assumption that the different studies are estimating different, 
yet related, treatment effects (Higgins & Green, 2006). Visual inspection of the forest 
plots will be used to investigate the possibility of statistical heterogeneity. This will be 
supplemented using, primarily, the I-squared statistic. This provides an estimate of the 
percentage of variability due to heterogeneity rather than a sampling error (Higgins et 
al., 2003). 95% confidence intervals will be calculated for I-squared, and a P value from a 
standard test for heterogeneity will be used to assess evidence of its presence.  
We will conduct a MTM which is a method of synthesizing information from a network 
of trials addressing the same question but involving different interventions. For a given 
comparison, say A versus B, direct evidence is provided by studies that compare these 
two treatments directly. However, indirect evidence is provided when studies that 
compare A versus C and B versus C are analyzed jointly. The combination of the direct 
and indirect into a single effect size can increase precision while randomization is 
respected. The combination of direct and indirect evidence for any given treatment 
comparison can be extended when ranking more than three types of treatments 
according to their effectiveness: every study contributes evidence about a subset of these 
treatments. We will perform MTM within a Bayesian framework (Ades et al., 2006). This 
enables us to estimate the probability for each intervention to be the best for each 
positive outcome, given the results of the MTM. The analysis will be performed using 
WinBUGS (MRC Biostatistics Unit, Cambridge, U.K., http://www.mrcbsu 
cam.ac.uk/bugs/winbugs/contents.shtml ).  
MTM should be used carefullly, and the underlying assumptions of the analysis should 
be investigated carefully. Key among these is that the network is coherent, meaning that 
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direct and indirect evidence on the same comparisons agree. Joint analysis of treatments 
can be misleading if the network is substantially incoherent, i.e., if there is disagreement 
between indirect and direct estimates. So, as a first step, we will calculate the difference 
between indirect and direct estimates in each closed loop formed by the network of trials 
as a measure of incoherence and we will subsequently examine whether there are any 
material discrepancies. In case of significant incoherence we will investigate possible 
sources of it. Incoherence may result as an uneven distribution of effect modifiers across 
groups of trials that compare different treatments. Therefore, we will investigate the 
distribution of clinical and methodological variables that we suspect may be potential 
sources of either heterogeneity or incoherence in each comparison-specific group of 
trials. 
 
Subgroup analysis 
We will carry out a subgroup analysis based on study treatment 
(combination/augmentation treatments vs monotherapy).  
 
Meta-regression analysis  
We will carry out a meta-regression analysis for sponsorship (Salanti et al., 2009).  
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Appendix 3 
 
Characteristics of included studies 
 
 
  
 
Study 
 
Drug 
A 
 
Drug 
B 
 
Drug 
C * 
 
Add-on 
 
F-up 
(wks) 
 
Setting 
 
Rating 
scale 
 
Diagnosis 
 
Sample 
 
Dose (mg) 
 
Sponsor  
A B C A B C 
Berk 1999 LIT OLZ - n 4 in MAS DSM-IV 15 15 - 800 mg 10 mg - unclear 
Berwaerts 2010 PAL# - PBO n 3 in & out YMRS DSM-IV 347  122 3-12 mg - Placebo Johnson & Johnson  
Bowden 1994 DVX LIT PBO n 3 in MRS RDC 69 36 74 max: 150 µg/mL max: 1.5 mEq/L Placebo Abbott 
Bowden 2005 QTP LIT PBO n 3 in YMRS DSM-IV 107 98 97 400-800 mg 0.6-1.4 mEq/L Placebo AstraZeneca 
Bowden 2006 DVX# - PBO n 3 in MRS DSM-IV 192 - 185 2961 mg (m) - Placebo Abbott 
Brown 1989 CBZ HAL - n 2 n/s YMRS DSM-III 8 9 - 200-1600 mg 10-80 mg - unclear 
Chengappa 2006 TOP - PBO y 3 out YMRS DSM-IV 143 - 144 50-400 mg - Placebo Otho-McNeil 
El Mallakh 2010 ARI  - PBO n 3 in YMRS DSM-IV 267 - 134 15-30 mg - Placebo BMS 
Freeman 1992 LIT DVX - n 3 n/s BPRS DSM-III-R 13 14 - 0.8-1.4 mEq/L 98 µg/mL (m) - unclear 
Garfinkel 1980 HAL LIT  - n 3 n/s BPRS Feighner 7 7 - 1.2 mEq/L (m) 28 mg (m) - unclear 
Hirschfeld 2004 RIS - PBO n 3 in YMRS DSM-IV 134 - 125 4.1 mg (m) - Placebo Johnson & Johnson 
Hirschfeld 2010 DVX# - PBO n 3 in MRS DSM-IV 147 - 78 77.9 µg/mL (m) - Placebo Abbott 
Houston 2009 OLZ - PBO y 6 in & out YMRS DSM-IV 101 - 101 5-20 mg - Placebo Eli Lilly 
Ichim 2000 LAM  LIT - n 4 in MRS DSM-IV 15 15 - 100 mg 800 mg - unclear 
Keck 2003a ZIP - PBO n 3 in MRS DSM-IV 140 - 70 80-160 mg - Placebo Pfizer 
Keck 2003b ARI - PBO n 3 in YMRS DSM-IV 130 - 132 15-30 mg - Placebo BMS 
Keck 2009 ARI LIT PBO n 3 in YMRS DSM-IV 155 160 165 15-30 mg 900-1500 mg Placebo BMS 
Khanna 2005 RIS - PBO n 3 in YMRS DSM-IV 146 - 145 1-6 mg - Placebo Johnson & Johnson 
Kushner 2006a TOP LIT PBO n 3 in YMRS DSM-IV 220 113 111 200-400 mg 1500 mg Placebo Otho-McNeil 
Kushner 2006b TOP - PBO n 3 in YMRS DSM-IV 214 - 100 400-600 mg - Placebo Otho-McNeil 
Kushner 2006c TOP - PBO n 3 in YMRS DSM-IV 109 - 106 400 mg - Placebo Otho-McNeil 
Kushner 2006d TOP LIT PBO n 3 in YMRS DSM-IV 116 114 112 400 mg 1500 mg Placebo Otho-McNeil 
Lerer 1987 CBZ LIT - n 4 n/s BPRS DSM-III 15 19 - 1400 mg (m) 0.87 mmol/l (m) - unclear 
Li 2008 QTP LIT - n 4 in YMRS CCMD-3 78 77 - 200-800 mg 0.6-1.2 mmol/l - AstraZeneca 
McIntyre 2005 QTP HAL PBO n 3 in YMRS DSM-IV 102 99 101 400-800 mg 2-8 mg Placebo AstraZeneca 
McIntyre 2009 ASE OLZ PBO n 3 in YMRS DSM-IV 194 190 105 10-20 mg 5-20 mg Placebo Schering-Plough 
Müller-O. 2000 DVX - PBO y 3 in YMRS ICD-10 69 - 67 20 mg/kg - Placebo GmbH 
Niufan 2008 OLZ LIT - n 4  in & out YMRS DSM-IV 69 71 - 5-20 mg 600-1800 mg - Eli Lilly 
  
Ortega-Soto 1993 CBZ  HAL - n 5 n/s MAS DSM-III-R 10 10 - 600-1600 mg 15-40 mg - unclear 
Pande 2000 GBT - PBO y 3 out YMRS DSM-IV 59 - 59 600-3600 mg - Placebo Warner-Lambert 
Perlis 2006 OLZ RIS - n 3 in YMRS DSM-IV 165 164 - 15-20 mg 3-6 mg - Eli Lilly 
Pope 1991 DVX - PBO n 3 n/s YMRS DSM-III-R 20 - 22 50-100 mg/L - Placebo unclear 
Potkin 2005 ZIP - PBO n 3 in MRS DSM-IV 140 - 66 80-160 mg - Placebo Pfizer 
Sachs 2002 RIS HAL PBO y 3 in YMRS DSM-IV 52 53 51 2-6 mg 4-12 mg - Janssen 
Sachs 2004 QTP - PBO y 3 in YMRS DSM-IV 91 - 100 200-800 mg - Placebo AstraZeneca 
Sachs 2006 ARI - PBO n 3 in YMRS DSM-IV 137 - 135 15-30 mg - Placebo BMS 
Segal 1998 RIS LIT HAL n 4 in MRS DSM-IV 15 15 15 6 mg 800-1200 mg 10 mg Janssen 
Shafti 2010 OLZ LIT - n 3 in MSRS DSM-IV-TR 20 20 - 20.52 mg (m) 0.78 mmol/l (m) - Independent 
Small 1991 CBZ LIT - n 6 in MRS DSM-III-R 27 25 - 1052 mg (m) 0.66 mmol/l (m) - NIMH 
Small 1995 CBZ HAL - y 3 in YMRS DSM-III-R 17 16  900-1200 mg 11-13.5 mg - unclear 
Smulevich 2005 RIS HAL PBO n 3 n/s YMRS DSM-IV 154 144 140 1-6 mg 2-12 mg Placebo Johnson & Johnson  
Tohen 1999 OLZ - PBO n 3 in YMRS DSM-IV 70  69 5-20 mg - Placebo Eli Lilly 
Tohen 2000 OLZ - PBO n 4  in & out YMRS DSM-IV 55 - 60 5-20 mg - Placebo Eli Lilly 
Tohen 2002a OLZ DVX - n 3 in YMRS DSM-IV 125 126 - 5-20 mg 500-2500 mg - Eli Lilly 
Tohen 2002b OLZ - PBO y 6  in & out YMRS DSM-IV 229 - 115 5-20 mg - Placebo Eli Lilly 
Tohen 2003 OLZ HAL - n 6  in & out YMRS DSM-IV 234 219 - 5-20 mg 3-15 mg - Eli Lilly 
Tohen 2008b OLZ - PBO y 6 in YMRS DSM-IV 58 - 60 10-30 mg - Placebo Eli Lilly 
Tohen 2008a OLZ DVX PBO n 3  in & out YMRS DSM-IV 215 201 105 5-20 mg 500-2500 mg Placebo Eli Lilly 
Vasudev 2000 CBZ  DVX - n 4 in YMRS DSM-III-R 15 15 - 800-1200 mg 800-1400 mg - unclear 
Vieta 2005 ARI HAL - n 3  in & out YMRS DSM-IV 175 172 - 15-30 mg 10-15 mg - BMS 
Vieta 2008 ARI - PBO y 6 n/s YMRS DSM-IV 253 - 131 15-30 mg - Placebo BMS 
Vieta 2010a PAL# QTP PBO n 3 n/s YMRS DSM-IV 195 193 105 3-12 mg 400-800 mg Placebo Johnson & Johnson 
Vieta 2010b ZIP HAL PBO n 3 in MRS DSM-IV 178 172 88 80-160 mg 8-30 mg Placebo Pfizer 
Weisler 2004 CBZ# - PBO n 3 in YMRS DSM-IV 101 - 103 200-1600 mg - Placebo Shire 
Weisler 2005 CBZ# - PBO n 3 in YMRS DSM-IV 122 - 117 200-1600 mg - Placebo Shire 
Yatham 2003 RIS - PBO y 3  in & out YMRS DSM-IV 75 - 76 4 mg (m) - Placebo Janssen 
Yatham 2007 QTP - PBO y 3 in YMRS DSM-IV 106 - 105 400-800 mg - Placebo AstraZeneca 
Young 2009 ARI HAL PBO n 3 in YMRS DSM-IV 167 165 153 15-30 mg 5-15 mg Placebo BMS 
Zajecka 2002 DVX OLZ - n 3 in MRS DSM-IV 63 57 - 20 mg/kg +/- 1000 mg 10-20 mg - Abbott 
  
D144CC00004 QTP# - PBO n 3 in & out YMRS DSM-IV-TR 155 - 161 400-800 mg - Placebo AstraZeneca 
SCAA2009 LAM LIT PBO n 6 n/s MRS DSM-IV 74 78 77 100 mg 0.7-1.3 mEq/L Placebo GSK 
SCAA2008 LAM LIT PBO n 3 in MRS DSM-IV 85 36 95 50 mg 0.8-1.3 mEq/L Placebo GSK 
NCT00129220 OLZ HAL PBO n 3 in & out YMRS DSM-IV 105 20 99 5-20 mg 2.5-10 mg Placebo Eli Lilly 
A 1281143 ZIP - PBO y 3 in YMRS DSM-IV 458 - 222 40-160 mg - Placebo Pfizer 
A 7501004 ASE OLZ PBO n 3 in YMRS DSM-IV 185 205 98 10-20 mg 5-20 mg Placebo Schering-Plough 
A 1280620 ZIP - PBO y 3 n/s MRS DSM-IV 102 - 103 80-160 mg - Placebo Pfizer 
A 1281147 ZIP OLZ -   n 3 n/s YMRS DSM-IV 15 14 - 120-160 mg 15-20 mg - Pfizer 
CR010855 PAL# - PBO y 6 n/s YMRS DSM-IV 150 - 150 3-12 mg - Placebo Johnson & Johnson 
 
 
Legend: 
 
n/s: not stated; in:  inpatients; out: outpatients;  in & out: both inpatients and outpatients;  * : or placebo; #: extended-release formulation; YMRS: Young 
Mania Rating Scale; MRS: Mania Rating Scale; MSRS: Manic State Rating Scale; BPRS: Brief Psychiatric Rating Scale; DSM III-R: Diagnostic Statistic Manual 
(Third Edition – Revised); DSM IV: Diagnostic Statistic Manual (Fourth Edition); DSM IV-TR: Diagnostic Statistic Manual (Fourth Edition – Text Revision); 
RDC: Research Diagnostic Criteria ; CCDM-3: Chinese Classification and Diagnosis Criteria of Mental Disorder, 3rd version; Feighner: Feighner criteria for 
mania (Feighner et al., 1972); F-up (wks): week of follow-up with outcome data available for analysis; (m): mean dose; Add-on: combination/augmentation 
strategy. 
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Appendix 4 
 
Risk of bias  
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We followed the recommended approach for assessing risk of bias in studies included in 
Cochrane reviews. It is a two-part tool, addressing the six specific domains (namely 
sequence generation, allocation concealment, blinding, incomplete outcome data, 
selective outcome reporting and ‘other issues’). Two of the items (adequacy of sequence 
generation and allocation concealment) assess the strength of the randomization process 
in preventing selection bias in the assignment of participants to interventions; the third 
item (blinding) assesses the influence of performance bias on the study results and the 
fourth the likelihood of incomplete outcome data, which raise the possibility of bias in 
effect estimates. The fifth item assesses selective reporting, the tendency to preferentially 
report statistically significant outcomes (this item requires a comparison of published 
data with trial protocols, when such are available). The final item refers to other sources 
of bias that are relevant in certain circumstances, such as, for example, sponsorship bias. 
Each domain includes one or more specific entries in a ‘Risk of bias’ table. Within each 
entry, the first part of the tool involves describing what was reported to have happened 
in the study. The second part of the tool involves assigning a judgement relating to the 
risk of bias for that entry. This is achieved by answering a pre-specified question about 
the adequacy of the study in relation to the entry, such that a judgement of ‘Yes’ 
indicates low risk of bias, ‘No’ indicates high risk of bias, and ‘Unclear’ indicates unclear 
or unknown risk of bias.  
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Domain  Description  Review authors’ 
judgement  
Sequence 
generation.  
Describe the method used to generate 
the allocation sequence in sufficient 
detail to allow an assessment of 
whether it should produce comparable 
groups.  
Was the allocation sequence 
adequately generated?  
Allocation 
concealment.  
Describe the method used to conceal 
the allocation sequence in sufficient 
detail to determine whether 
intervention allocations could have 
been foreseen in advance of, or during, 
enrolment.  
Was allocation adequately 
concealed?  
Blinding of 
participants, 
personnel and 
outcome assessors   
Describe all measures used, if any, to 
blind study participants and personnel 
from knowledge of which intervention 
a participant received. Provide any 
information relating to whether the 
intended blinding was effective.  
Was knowledge of the 
allocated intervention 
adequately prevented during 
the study?  
Incomplete outcome 
data Assessments 
should be made for 
each main outcome (or 
class of outcomes).   
Describe the completeness of outcome 
data for each main outcome, including 
attrition and exclusions from the 
analysis. State whether attrition and 
exclusions were reported, the numbers 
in each intervention group (compared 
with total randomized participants), 
reasons for attrition/exclusions where 
reported, and any re-inclusions in 
analyses performed by the review 
authors.  
Were incomplete outcome 
data adequately addressed?  
Selective outcome 
reporting.  
State how the possibility of selective 
outcome reporting was examined by 
the review authors, and what was 
found.  
Are reports of the study free 
of suggestion of selective 
outcome reporting?  
Other sources of 
bias.  
State any important concerns about 
bias not addressed in the other 
domains in the tool.  
Was the study apparently 
free of other problems that 
could put it at a high risk of 
bias?  
 Risk of bias graph: it is a plot of the distribution of judgments (Yes, Unclear and 
No) across studies for each risk of bias item.  
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Appendix 5 
 
 
 
 
Networks for acceptability and  
efficacy as binary outcome (response rate)  
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1
10
11
12
13
14
2
3
4
5
6
7
8
9
Placebo
Aripiprazole
Gabapentin
Lamotrigine Olanzapine
Topiramate
Quetiapine
Carbamazepine
Asenapine
Risperidone
Divalproex
Ziprasidone
Haloperidol
Lithium
Network of eligible comparisons in the multiple-treatments meta-analysis for acceptability (65 studies)
 
Network of eligible comparisons in the multiple-treatments meta-analysis for responders (42 studies)
ARI
RISPAL
ASE
CBZ
TOP
PBO
LIT
HAL
QTP
ZIP
OLZ
LAM
DVP
Placebo
Aripiprazole
Lamotrigine Olanzapine
Topiramate
Quetiapine
Carbamazepine
Asenapine
Risperidone
Divalproex Ziprasidone
Haloperidol
Lithium
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Appendix 6 
 
 
Values of I2 and corresponding confidence intervals  
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EFFICACY - Continuous response 
Comparison I2 ** 95% CI 
Aripiprazole vs Placebo 27.77% 0.00 – 70.18% 
Aripiprazole vs Haloperidol 0.00% NA 
Placebo vs Quetiapine 35.98% 0.00 – 74.43% 
Lithium vs Quetiapine 56.19% NA 
Placebo vs Ziprasidone 76.56% 42.93 – 90.37% 
Lithium vs Olanzapine 89.23% 70.70 – 96.04% 
Placebo vs Olanzapine 39.74% 0.00 – 72.26% 
Olanzapine vs Divalproex 0.00% 0.00 – 81.58% 
Haloperidol vs Olanzapine 0.00% NA 
Placebo vs Risperidone 68.95% 35.11 – 85.15% 
Placebo vs Divalproex 0.00% 0.00 – 71.93% 
Haloperidol vs Carbamazepine 0.00% 0.00 – 0.00% 
Lithium vs Lamotrigine 0.00% 0.00 – 59.95% 
Placebo vs Topiramate 0.00% 0.00 – 31.94% 
Lithium vs Carbamazepine 0.00% NA 
Placebo vs Lithium 29.46% 0.00 – 71.15% 
Placebo vs Haloperidol 58.58% 0.00 – 83.21% 
Haloperidol vs Risperidone 0.00% 0.00 – 87.97% 
Placebo vs Asenapine 0.00% NA 
Olanzapine vs Asenapine 0.00% NA 
Placebo vs Lamotrigine 0.00% NA 
Lithium vs Topiramate 0.00% NA 
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ACCEPTABILITY - Binary droupout 
Comparison I2 ** 95% CI 
Aripiprazole vs Placebo 62.60% 9.11 – 84.61% 
Aripiprazole vs Haloperidol 84.07% NA 
Placebo vs Quetiapine 63.07% 10.43 – 84.77% 
Lithium vs Quetiapine 19.97% NA 
Placebo vs Ziprasidone 67.63% 16.25 – 87.49% 
Lithium vs Olanzapine 1.03% 0.00 – 89.71% 
Placebo vs Olanzapine 60.54% 18.06 – 80.99% 
Olanzapine vs Divalproex 0.00% NA 
Haloperidol vs Olanzapine 62.59% NA 
Placebo vs Risperidone 43.76% 0.00 – 76.34% 
Placebo vs Divalproex 0.00% 0.00 – 59.12% 
Haloperidol vs Carbamazepine 67.47% 0.00 – 90.59% 
Lithium vs Lamotrigine 81.99% 44.42 – 94.17% 
Placebo vs Topiramate 5.15% 0.00 – 80.27% 
Lithium vs Haloperidol 54.22% NA 
Lithium vs Carbamazepine 71.24% NA 
Placebo vs Lithium 60.46% 9.36 – 82.75% 
Placebo vs Haloperidol 49.54% 0.00 – 79.96% 
Haloperidol vs Risperidone 24.07% 0.00- 92.10% 
Placebo vs Asenapine 0.00% NA 
Olanzapine vs Asenapine 0.00% NA 
Placebo vs Lamotrigine 0.00% NA 
Lithium vs Topiramate 38.08% NA 
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EFFICACY - Binary response 
Comparison I2 ** 95% CI 
Aripiprazole vs Placebo 39.02% 0.00 – 75.79% 
Aripiprazole vs Haloperidol 49.55% NA 
Placebo vs Quetiapine 11.45% 0.00 – 77.53% 
Lithium vs Quetiapine 68.08% NA 
Placebo vs Ziprasidone 50.08% 0.00 – 81.69% 
Placebo vs Olanzapine 43.62% 0.00 – 75.05% 
Olanzapine vs Divalproex 56.59% NA 
Haloperidol vs Olanzapine  4.41% NA 
Placebo vs Risperidone 74.05% 40.82 – 88.62% 
Lithium vs Divalproex 58.28% NA 
Placebo vs Divalproex 42.13% 0.00 – 78.70% 
Lithium vs Olanzapine 63.16% NA 
 
 
               
Legend. We have excluded subgroups of head-to-head comparisons with undefined I2, that is 
. ** The variation in OR attributable to heterogeneity; CI  Confidence Interval.  
Note: between group heterogeneity not calculated; only valid with inverse variance method 
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Appendix 7 
 
 
Multiple-treatments meta-analysis  
(combination of direct and indirect comparisons) 
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Code names for NODES           
 
1 Aripiprazole  
2 Placebo          
3 Lithium         
4 Haloperidol  
5 Quetiapine   
6 Ziprasidone   
7 Olanzapine    
8  Lamotrigine  
9 Divalproex  
10 Risperidone+Paliperidone  
11 Asenapine  
12 Carbamazepine  
13 Topiramate  
14 Gabapentin 
 
 
ANALYSIS of EFFICACY as CONTINUOUS OUTCOME (Standardized Mean 
Difference – SMD) 
 
NODE          2.5%  MEDIAN 97.5%  
 
SMD[1,2]   -0.5082 -0.3711 -0.2329 
SMD[1,3]   -0.1724 0.003057 0.1824 
SMD[1,4]   0.0235  0.1876  0.356 
SMD[1,5]   -0.1959 -0.002  0.1915 
SMD[1,6]   -0.3875 -0.1755 0.04159 
SMD[1,7]   -0.1102 0.06387 0.2348 
SMD[1,8]   -0.5841 -0.2934 -0.001902 
SMD[1,9]   -0.3823 -0.1673 0.04741 
SMD[1,10]  -0.04877 0.1324  0.3142 
SMD[1,11]  -0.3377 -0.07191 0.1959 
SMD[1,12]  -0.2942 -0.01183 0.2577 
SMD[1,13]  -0.6601 -0.4467 -0.2322 
SMD[1,14]  -1.212  -0.6922 -0.1748 
SMD[2,3]   0.247  0.3738  0.503 
SMD[2,4]   0.4319  0.5591  0.6862 
SMD[2,5]   0.2281  0.3688  0.5133 
SMD[2,6]   0.03014 0.1954  0.3664 
SMD[2,7]   0.3235  0.4349  0.5433 
SMD[2,8]   -0.1824 0.0774  0.3381 
SMD[2,9]   0.03554 0.204  0.3698 
SMD[2,10]  0.3807  0.5033  0.6272 
SMD[2,11]  0.06895 0.3  0.5315 
SMD[2,12]  0.1083  0.3593  0.599 
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NODE  LOW  MEDIAN HIGH 
 
SMD[2,13] -0.2418 -0.0754 0.09268 
SMD[2,14]  -0.823  -0.3229 0.1788 
SMD[3,4]   0.01392 0.1854  0.3554 
SMD[3,5]   -0.1788 -0.004925 0.169 
SMD[3,6]   -0.386  -0.178  0.03253 
SMD[3,7]   -0.09744 0.06094 0.2153 
SMD[3,8]   -0.5558 -0.2968 -0.03764 
SMD[3,9]   -0.3732 -0.1701 0.02979 
SMD[3,10]  -0.04201 0.1291  0.3 
SMD[3,11]  -0.3359 -0.07399 0.1856 
SMD[3,12]  -0.2847 -0.01471 0.2434 
SMD[3,13]  -0.6425 -0.4491 -0.2577 
SMD[3,14]  -1.213  -0.696  -0.1824 
SMD[4,5]   -0.3701 -0.1904 -0.009481 
SMD[4,6]   -0.5598 -0.3636 -0.1624 
SMD[4,7]   -0.278  -0.1241 0.02695 
SMD[4,8]   -0.7672 -0.4822 -0.1948 
SMD[4,9]   -0.5586 -0.3555 -0.1521 
SMD[4,10]  -0.217  -0.05596 0.106 
SMD[4,11]  -0.518  -0.2596 -3.552E-4 
SMD[4,12]  -0.4648 -0.2003 0.05377 
SMD[4,13]  -0.8431 -0.6342 -0.4262 
SMD[4,14]  -1.396  -0.8819 -0.3646 
SMD[5,6]   -0.3918 -0.1732 0.04701 
SMD[5,7]   -0.113  0.06636 0.2392 
SMD[5,8]   -0.5802 -0.2915 -9.06E-4 
SMD[5,9]   -0.3846 -0.1651 0.05077 
SMD[5,10]  -0.04295 0.1342  0.3105 
SMD[5,11]  -0.3406 -0.06855 0.1991 
SMD[5,12]  -0.2964 -0.009827 0.2647 
SMD[5,13]  -0.6616 -0.4442 -0.2294 
SMD[5,14]  -1.212  -0.6909 -0.17 
SMD[6,7]   0.03479 0.2394  0.4346 
SMD[6,8]   -0.4275 -0.1181 0.1885 
SMD[6,9]   -0.2315 0.008507 0.2402 
SMD[6,10]  0.09958 0.3081  0.5118 
SMD[6,11]  -0.1817 0.1049  0.3878 
SMD[6,12]  -0.139  0.1636  0.4493 
SMD[6,13]  -0.5105 -0.2709 -0.03524 
SMD[6,14]  -1.048  -0.5181 0.008375 
SMD[7,8]   -0.6362 -0.3574 -0.07597 
SMD[7,9]   -0.4016 -0.2315 -0.05893 
SMD[7,10]  -0.08404 0.06852 0.2228 
SMD[7,11]  -0.3604 -0.1353 0.09616 
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NODE LOW  MEDIAN HIGH 
 
SMD[7,12]  -0.3429 -0.0762 0.1831 
SMD[7,13]  -0.7048 -0.5106 -0.31 
SMD[7,14]  -1.269  -0.7573 -0.2418 
SMD[8,9]   -0.1803 0.127  0.4285 
SMD[8,10]  0.1425  0.4257  0.7091 
SMD[8,11]  -0.1244 0.2223  0.5675 
SMD[8,12]  -0.07889 0.2817  0.6282 
SMD[8,13]  -0.4573 -0.1523 0.1483 
SMD[8,14]  -0.963  -0.4005 0.1572 
SMD[9,10]  0.09626 0.2997  0.5049 
SMD[9,11]  -0.1779 0.09596 0.3718 
SMD[9,12]  -0.132  0.1551  0.4357 
SMD[9,13]  -0.5153 -0.2791 -0.0425 
SMD[9,14]  -1.05  -0.526  0.005634 
SMD[10,11]  -0.4614 -0.2028 0.05409 
SMD[10,12]  -0.4204 -0.1446 0.1214 
SMD[10,13]  -0.7844 -0.5789 -0.3721 
SMD[10,14]  -1.338  -0.8264 -0.3079 
SMD[11,12]  -0.283  0.05971 0.3869 
SMD[11,13]  -0.6598 -0.3753 -0.09134 
SMD[11,14]  -1.172  -0.622  -0.06794 
SMD[12,13]  -0.7235 -0.4343 -0.1356 
SMD[12,14]  -1.235  -0.6804 -0.1195 
SMD[13,14]  -0.775  -0.2469 0.2778 
 
 
ANALYSIS of ACCEPTABILITY AS BINARY OUTCOME (Odds Ratio – OR) 
 
NODE          2.5%  MEDIAN 97.5%  
 
OR[1,2]   0.5464  0.7583  1.055  
OR[1,3]   0.4885  0.7531  1.158   
OR[1,4]   0.5963  0.8899  1.33  
OR[1,5]   0.7393  1.184  1.907   
OR[1,6]   0.5074  0.8331  1.387   
OR[1,7]   0.8607  1.304  1.977   
OR[1,8]   0.3208  0.6355  1.255   
OR[1,9]   0.638  1.037  1.687   
OR[1,10]   0.7994  1.251  1.969   
OR[1,11]   0.4034  0.7669  1.46   
OR[1,12]   0.5003  0.9653  1.858   
OR[1,13]   0.3027  0.508  0.858  
OR[1,14]   0.1412  0.429  1.293  
OR[2,1]   0.9481  1.319  1.83   
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NODE   LOW  MEDIAN HIGH 
 
OR[2,3]   0.7248  0.9928  1.355   
OR[2,4]   0.8607  1.174  1.596   
OR[2,5]   1.105  1.562  2.219   
OR[2,6]   0.7484  1.098  1.629   
OR[2,7]   1.316  1.72  2.251   
OR[2,8]   0.4585  0.8367  1.537   
OR[2,9]   0.9481  1.368  1.968   
OR[2,10]   1.202  1.65  2.271   
OR[2,11]   0.5818  1.01  1.767   
OR[2,12]   0.7118  1.273  2.271   
OR[2,13]   0.4448  0.6703  1.01   
OR[2,14]   0.1957  0.5661  1.628   
OR[3,1]   0.8632  1.328  2.047   
OR[3,2]   0.738  1.007  1.38   
OR[3,4]    0.7765  1.183  1.801   
OR[3,5]   1.021  1.573  2.449   
OR[3,6]   0.679  1.106  1.835   
OR[3,7]   1.167  1.733  2.588   
OR[3,8]   0.461  0.8435  1.552   
OR[3,9]   0.8668  1.379  2.183   
OR[3,10]   1.075  1.661  2.59   
OR[3,11]   0.5422  1.017  1.923  
OR[3,12]   0.6939  1.281  2.379   
OR[3,13]   0.4235  0.6745  1.078   
OR[3,14]   0.1893  0.569  1.721   
OR[4,1]   0.752  1.124  1.677   
OR[4,2]   0.6267  0.852  1.162   
OR[4,3]   0.5552  0.8454  1.288   
OR[4,5]     0.8573  1.332  2.074   
OR[4,6]   0.5921  0.9354  1.497   
OR[4,7]   1.01  1.467  2.129   
OR[4,8]   0.3634  0.7128  1.398   
OR[4,9]   0.7289  1.166  1.864   
OR[4,10]   0.9361  1.406  2.121   
OR[4,11]   0.4626  0.8602  1.612   
OR[4,12]   0.5786  1.085  2.027   
OR[4,13]   0.3429  0.5712  0.9482   
OR[4,14]   0.1602  0.4829  1.449   
OR[5,1]   0.5244  0.8443  1.353   
OR[5,2]   0.4506  0.6401  0.9053   
OR[5,3]   0.4084  0.6356  0.9792   
OR[5,4]   0.4822  0.7506  1.167   
OR[5,6]   0.4212  0.7032  1.184   
OR[5,7]   0.7107  1.101  1.699   
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NODE   LOW  MEDIAN HIGH 
 
OR[5,8]   0.2689  0.5352  1.066   
OR[5,9]   0.5274  0.8757  1.441   
OR[5,10]   0.6729  1.057  1.65   
OR[5,11]   0.3363  0.6468  1.243   
OR[5,12]   0.4174  0.8139  1.579   
OR[5,13]   0.2507  0.429  0.7259   
OR[5,14]   0.1187  0.3621  1.097   
OR[6,1]   0.7212  1.2  1.971   
OR[6,2]     0.614  0.9107  1.336   
OR[6,3]   0.545  0.9038  1.473   
OR[6,4]   0.6681  1.069  1.689   
OR[6,5]     0.8445  1.422  2.374   
OR[6,7]   0.9857  1.566  2.459   
OR[6,8]   0.3695  0.7621  1.561   
OR[6,9]   0.7277  1.245  2.098   
OR[6,10]   0.9118  1.501  2.463   
OR[6,11]   0.4663  0.9202  1.792   
OR[6,12]   0.5761  1.157  2.293   
OR[6,13]   0.345  0.6103  1.063   
OR[6,14]   0.1661  0.515  1.571   
OR[7,1]   0.5058  0.767  1.162   
OR[7,2]   0.4443  0.5815  0.7602   
OR[7,3]   0.3864  0.5769  0.8567   
OR[7,4]   0.4697  0.6819  0.9904   
OR[7,5]     0.5886  0.9083  1.407   
OR[7,6]   0.4067  0.6387  1.015   
OR[7,8]   0.2525  0.4861  0.9449   
OR[7,9]   0.5291  0.7946  1.196   
OR[7,10]   0.6508  0.9591  1.421   
OR[7,11]   0.3384  0.5869  1.022   
OR[7,12]   0.3942  0.7393  1.384   
OR[7,13]   0.2401  0.3898  0.6342  
OR[7,14]   0.1106  0.3293  0.9788   
OR[8,1]   0.797  1.574  3.117   
OR[8,2]   0.6506  1.195  2.181   
OR[8,3]   0.6442  1.186  2.169   
OR[8,4]   0.7155  1.403  2.752   
OR[8,5]       0.9385  1.869  3.719   
OR[8,6]   0.6408  1.312  2.706   
OR[8,7]   1.059  2.057  3.96   
OR[8,9]   0.809  1.633  3.267   
OR[8,10]   0.9985  1.971  3.898   
OR[8,11]   0.5292  1.207  2.731   
OR[8,12]   0.6621  1.521  3.447   
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NODE   LOW  MEDIAN HIGH 
 
OR[8,13]   0.3921  0.8  1.634   
OR[8,14]   0.1992  0.6739  2.279   
OR[9,1]   0.5929  0.9643  1.567   
OR[9,2]   0.5082  0.7312  1.055  
OR[9,3]   0.4581  0.7253  1.154   
OR[9,4]   0.5365  0.8578  1.372   
OR[9,5]   0.6941  1.142  1.896   
OR[9,6]     0.4765  0.803  1.374   
OR[9,7]   0.8363  1.258  1.89   
OR[9,8]   0.3061  0.6124  1.236   
OR[9,10]   0.7523  1.207  1.96   
OR[9,11]   0.3865  0.7384  1.42   
OR[9,12]   0.4791  0.9308  1.814   
OR[9,13]   0.2843  0.49  0.8465   
OR[9,14]   0.1347  0.4139  1.27   
OR[10,1]   0.5079  0.7993  1.251   
OR[10,2]   0.4403  0.6061  0.8317   
OR[10,3]   0.3861  0.6019  0.93  
OR[10,4]   0.4716  0.7114  1.068  
OR[10,5]   0.6059  0.9458  1.486  
OR[10,6]   0.4061  0.6664  1.097  
OR[10,7]   0.704  1.043  1.537  
OR[10,8]   0.2565  0.5074  1.002  
OR[10,9]   0.5102  0.8286  1.329  
OR[10,11]   0.3257  0.612  1.152  
OR[10,12]   0.3979  0.7718  1.486  
OR[10,13]   0.2416  0.4062  0.678  
OR[10,14]   0.1135  0.3435  1.024  
OR[11,1]   0.6849  1.304  2.479  
OR[11,2]   0.5659  0.9897  1.719  
OR[11,3]   0.5201  0.9837  1.844  
OR[11,4]   0.6204  1.163  2.162  
OR[11,5]   0.8046  1.546  2.974  
OR[11,6]   0.5581  1.087  2.144  
OR[11,7]   0.9789  1.704  2.955   
OR[11,8]   0.3661  0.8283  1.89  
OR[11,9]   0.7044  1.354  2.588  
OR[11,10]   0.868  1.634  3.07  
OR[11,12]   0.5655  1.262  2.806   
OR[11,13]   0.3338  0.663  1.322   
OR[11,14]   0.1697  0.5596  1.853   
OR[12,1]   0.5381  1.036  1.999   
OR[12,2]   0.4403  0.7858  1.405   
OR[12,3]   0.4203  0.7809  1.441   
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NODE   LOW  MEDIAN HIGH 
 
OR[12,4]   0.4933  0.9219  1.728   
OR[12,5]   0.6332  1.229  2.396   
OR[12,6]   0.4362  0.8641  1.736   
OR[12,7]   0.7226  1.353  2.537   
OR[12,8]   0.2902  0.6575  1.51  
OR[12,9]   0.5514  1.074  2.088  
OR[12,10]   0.6734  1.296  2.513  
OR[12,11]   0.3564  0.7926  1.768  
OR[12,13]   0.2617  0.5267  1.063  
OR[12,14]   0.1328  0.445  1.486  
OR[13,1]   1.165  1.969  3.304  
OR[13,2]   0.9899  1.492  2.248  
OR[13,3]   0.9277  1.483  2.361  
OR[13,4]   1.055  1.751  2.916  
OR[13,5]   1.378  2.331  3.989  
OR[13,6]   0.941  1.639  2.898  
OR[13,7]   1.577  2.565  4.164  
OR[13,8]   0.612  1.25  2.551  
OR[13,9]   1.181  2.041  3.517  
OR[13,10]   1.475  2.462  4.14  
OR[13,11]   0.7563  1.508  2.996  
OR[13,12]   0.9409  1.899  3.821  
OR[13,14]   0.2716  0.8443  2.613  
OR[14,1]   0.7734  2.331  7.081  
OR[14,2]   0.6144  1.766  5.109  
OR[14,3]   0.581  1.758  5.284  
OR[14,4]   0.69  2.071  6.242  
OR[14,5]   0.9121  2.762  8.424  
OR[14,6]   0.6365  1.942  6.022  
OR[14,7]   1.022  3.037  9.043  
OR[14,8]   0.4387  1.484  5.02  
OR[14,9]   0.7872  2.416  7.423  
OR[14,10]   0.9762  2.911  8.811  
OR[14,11]   0.5396  1.787  5.891  
OR[14,12]   0.6731  2.247  7.529  
OR[14,13]   0.3827  1.184  3.682  
 
 
ANALYSIS of EFFICACY AS BINARY OUTCOME (Odds Ratio – OR) 
 
NODE   LOW  MEDIAN HIGH 
 
OR[1,2]   1.518  2.004  2.66 
OR[1,3]   0.7177  1.103  1.686 
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NODE   LOW  MEDIAN HIGH 
 
OR[1,4]   0.6276  0.8893  1.252 
OR[1,5]   0.6729  0.9974  1.476 
OR[1,6]   0.9401  1.455  2.238 
OR[1,7]   0.6447  0.9217  1.322 
OR[1,8]   0.2767  1.457  7.826 
OR[1,9]   0.6553  1.009  1.543 
OR[1,10]   0.6348  0.935  1.38 
OR[1,11]   0.583  1.182  2.393 
OR[1,12]   0.4175  0.8094  1.65 
OR[1,13]   1.092  2.601  6.245 
OR[2,1]   0.376  0.499  0.6589 
OR[2,3]   0.3817  0.55  0.7868 
OR[2,4]   0.3324  0.4437  0.5859 
OR[2,5]   0.3701  0.4975  0.6655 
OR[2,6]   0.5143  0.7261  1.012 
OR[2,7]   0.3619  0.4596  0.5846 
OR[2,8]   0.1392  0.7275  3.852 
OR[2,9]   0.3588  0.5037  0.6973 
OR[2,10]   0.3527  0.467  0.6158 
OR[2,11]   0.3065  0.5891  1.13 
OR[2,12]   0.2201  0.4049  0.7731 
OR[2,13]   0.5669  1.297  2.98 
OR[3,1]   0.593  0.9066  1.393 
OR[3,2]   1.271  1.818  2.62 
OR[3,4]   0.5217  0.8056  1.252 
OR[3,5]   0.6038  0.9042  1.362 
OR[3,6]   0.8068  1.319  2.152 
OR[3,7]   0.5609  0.8354  1.254 
OR[3,8]   0.2655  1.322  6.715 
OR[3,9]   0.5802  0.9151  1.441 
OR[3,10]   0.5447  0.848  1.33 
OR[3,11]   0.5143  1.071  2.236 
OR[3,12]   0.3646  0.737  1.553 
OR[3,13]   0.9637  2.357  5.831 
OR[4,1]   0.7989  1.124  1.593 
OR[4,2]   1.707  2.254  3.008 
OR[4,3]   0.7989  1.241  1.917 
OR[4,5]   0.7664  1.121  1.651 
OR[4,6]   1.083  1.636  2.461 
OR[4,7]   0.7438  1.037  1.459 
OR[4,8]   0.3099  1.64  8.837 
OR[4,9]   0.7431  1.135  1.727 
OR[4,10]   0.7298  1.053  1.523 
OR[4,11]   0.6585  1.328  2.682 
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NODE   LOW  MEDIAN HIGH 
 
OR[4,12]   0.4732  0.9123  1.848 
OR[4,13]   1.23  2.926  7.082 
OR[5,1]   0.6777  1.003  1.486 
OR[5,2]   1.503  2.01  2.702 
OR[5,3]   0.7343  1.106  1.656 
OR[5,4]   0.6057  0.8918  1.305 
OR[5,6]   0.9321  1.46  2.268 
OR[5,7]   0.6434  0.9231  1.336 
OR[5,8]   0.2796  1.463  7.861 
OR[5,9]   0.654  1.012  1.556 
OR[5,10]   0.6447  0.9378  1.368 
OR[5,11]   0.5834  1.185  2.415 
OR[5,12]   0.4144  0.8144  1.665 
OR[5,13]   1.087  2.608  6.299 
OR[6,1]   0.4468  0.6874  1.064 
OR[6,2]   0.9882  1.377  1.944 
OR[6,3]   0.4646  0.7583  1.24 
OR[6,4]   0.4063  0.6112  0.9238 
OR[6,5]   0.4409  0.6849  1.073 
OR[6,7]   0.4232  0.6333  0.9622 
OR[6,8]   0.1873  1  5.413 
OR[6,9]   0.4332  0.6938  1.11 
OR[6,10]   0.4184  0.6425  0.9985 
OR[6,11]   0.391  0.8109  1.694 
OR[6,12]   0.2797  0.558  1.167 
OR[6,13]   0.7349  1.79  4.417 
OR[7,1]   0.7564  1.085  1.551 
OR[7,2]   1.711  2.176  2.763 
OR[7,3]   0.7974  1.197  1.783 
OR[7,4]   0.6853  0.9645  1.345 
OR[7,5]   0.7485  1.083  1.554 
OR[7,6]   1.039  1.579  2.363 
OR[7,8]   0.3012  1.584  8.432 
OR[7,9]   0.7603  1.095  1.559 
OR[7,10]   0.7203  1.014  1.425 
OR[7,11]   0.6704  1.282  2.432 
OR[7,12]   0.4585  0.8816  1.756 
OR[7,13]   1.197  2.818  6.693 
OR[8,1]   0.1278  0.6865  3.614 
OR[8,2]   0.2596  1.375  7.184 
OR[8,3]   0.149  0.7562  3.767 
OR[8,4]   0.1132  0.6099  3.227 
OR[8,5]   0.1272  0.6833  3.577 
OR[8,6]   0.1848  0.9997  5.339 
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NODE   LOW  MEDIAN HIGH 
 
OR[8,7]   0.1186  0.6314  3.32 
OR[8,9]   0.1285  0.6901  3.675 
OR[8,10]   0.1188  0.641  3.413 
OR[8,11]   0.1382  0.8095  4.751 
OR[8,12]   0.09614 0.558  3.241 
OR[8,13]   0.2778  1.776  11.13 
OR[9,1]   0.6481  0.991  1.526 
OR[9,2]   1.434  1.985  2.787 
OR[9,3]   0.6938  1.093  1.724 
OR[9,4]   0.5789  0.8812  1.346 
OR[9,5]   0.6428  0.988  1.529 
OR[9,6]   0.9006  1.441  2.308 
OR[9,7]   0.6416  0.9135  1.315 
OR[9,8]   0.2722  1.449  7.782 
OR[9,10]   0.6103  0.9275  1.424 
OR[9,11]   0.572  1.172  2.41 
OR[9,12]   0.4121  0.8053  1.634 
OR[9,13]   1.068  2.578  6.312 
OR[10,1]   0.7246  1.07  1.575 
OR[10,2]   1.624  2.141  2.835 
OR[10,3]   0.7519  1.179  1.836 
OR[10,4]   0.6564  0.9501  1.37 
OR[10,5]   0.7309  1.066  1.551 
OR[10,6]   1.002  1.556  2.39 
OR[10,7]   0.7015  0.9858  1.388 
OR[10,8]   0.2932  1.56  8.416 
OR[10,9]   0.7025  1.078  1.639 
OR[10,11]   0.6264  1.264  2.544 
OR[10,12]   0.4448  0.8683  1.755 
OR[10,13]   1.159  2.784  6.69 
OR[11,1]   0.4179  0.8462  1.715 
OR[11,2]   0.8849  1.697  3.263 
OR[11,3]   0.4472  0.934  1.945 
OR[11,4]   0.3729  0.7532  1.519 
OR[11,5]   0.4141  0.8436  1.714 
OR[11,6]   0.5902  1.233  2.558 
OR[11,7]   0.4113  0.7803  1.492 
OR[11,8]   0.2105  1.235  7.236 
OR[11,9]   0.4149  0.853  1.748 
OR[11,10]   0.3932  0.791  1.596 
OR[11,12]   0.2856  0.6877  1.738 
OR[11,13]   0.7734  2.201  6.36 
OR[12,1]   0.6061  1.235  2.396 
OR[12,2]   1.294  2.47  4.544 
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NODE   LOW  MEDIAN HIGH 
 
OR[12,3]   0.644  1.357  2.743 
OR[12,4]   0.5411  1.096  2.113 
OR[12,5]   0.6006  1.228  2.414 
OR[12,6]   0.8567  1.792  3.575 
OR[12,7]   0.5697  1.134  2.181 
OR[12,8]   0.3085  1.792  10.4 
OR[12,9]   0.6119  1.242  2.427 
OR[12,10]   0.57  1.152  2.248 
OR[12,11]   0.5753  1.454  3.501 
OR[12,13]   1.117  3.198  8.896 
OR[13,1]   0.1601  0.3845  0.9155 
OR[13,2]   0.3356  0.7712  1.764 
OR[13,3]   0.1715  0.4242  1.038 
OR[13,4]   0.1412  0.3418  0.8131 
OR[13,5]   0.1588  0.3834  0.9196 
OR[13,6]   0.2264  0.5585  1.361 
OR[13,7]   0.1494  0.3549  0.8356 
OR[13,8]   0.08992 0.5631  3.6 
OR[13,9]   0.1584  0.388  0.9365 
OR[13,10]   0.1495  0.3592  0.8631 
OR[13,11]   0.1573  0.4543  1.293 
OR[13,12]   0.1124  0.3127  0.8956 
 
 
92 
 
 
 
 
 
 
 
 
 
Appendix 8 
 
 
Statistical inconsistency (with graphs) 
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The great majority of loops was consistent, since their 95% CIs seem to include 0 (that is 
the direct estimate of the summary effect does not differentiate from the indirect 
estimate) according to the forest plots. Analysis of inconsistency indicated that there was 
inconsistency in five out of a total of 31 loops for efficacy measured as a continuous 
outcome (aripiprazole–lithium–haloperidol; placebo–lithium–haloperidol; lithium–
divalproex–carbamazepine; lithium–haloperidol–carbamazepine; placebo–divalproex–
carbamazepine), in three out of 33 loops for acceptability (aripiprazole-placebo-
haloperidol; olanzapine-placebo-risperidone; quetiapine-placebo-haloperidol), but none 
for binary efficacy (18 loops). Data extraction and data entry were found to be correct. 
We could not identify any important variables that differed across comparisons in those 
loops, but the number of included studies was very small in the inconsistent loops. We 
also fit the model for the continuous efficacy data assuming no consistency. The models 
(with and without consistency) were very similar in terms of balance between model fit 
and complexity fit (Deviance Information Criteria 265.1 and 264.1 respectively). Some 
different parameterizations of the three arm trials did not considerably changed the 
similarity of the two models.  
 
 
 
 
 
 
 
 
 
 
 
 
Code Name 
a Aripiprazole 
b Placebo 
c Lithium 
d Haloperidol 
e Quetiapine 
f Ziprasidone 
g Olanzapine 
h  Lamotrigine 
i Divalproex 
j Risperidone (and Paliperidone) 
k Asenapine 
l Carbamazepine 
m Topiramate 
n Gabapentin 
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Continuous efficacy data 
 Continuous Data
-3 -2 -1 0 1 2 3
1st order loops
abc
abd
acd
bcg
bcd
bci
bce
bcj
bcl
bch
bcn
bdg
bgi
bgj
bgk
bde
bdf
bdj
bdl
bil
bej
cdg
cgi
cgj
cde
cdj
cdl
cil
cej
dgj
dej
Evaluation of coherence within first order closed loops
Estimates with 95% confidence intervals
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Binary efficacy data (response rate) 
 
-3 -2 -1 0 1 2 3
1st order loops
abc
abd
bcg
bci
bce
bdg
bgi
bgj
bgk
bde
bdf
bdj
bdl
bil
bej
cgi
dgj
dej
Evaluation of coherence within first order closed loops
Estimates with 95% confidence intervals
Binary reponse
 
 
 
 
 
 
96 
 
 
 
 
Binary acceptability data (dropout rate) 
 
-4 -2 0 2 4
1st order loops
abc
abd
acd
bcg
bcd
bci
bce
bcj
bcl
bch
bcm
bfg
bdf
bdg
bgi
bgj
bgk
bde
bdj
bdl
bil
bej
cdg
cgi
cgj
cde
cdj
cdl
cil
cej
dfg
dgj
dej
Evaluation of coherence within first order closed loops
Estimates with 95% confidence intervals
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Appendix 9 
 
 
Sensitivity analysis 
Combination/augmentation treatment strategies  
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Meta-analysis of Continuous Response Outcome Excluding Studies with 
Combination Strategy 
 
Code Name Code Name 
1 Aripiprazole 8  Lamotrigine 
2 Placebo 9 Divalproex 
3 Lithium 10 Risperidone 
4 Haloperidol 11 Asenapine 
5 Quetiapine 12 Carbamazepine 
6 Ziprasidone 14 Topiramate 
7 Olanzapine 16 Paliperidone 
 
 
 
 
 
           Study     |     SMD   [95% Conf. Interval]     % Weight 
---------------------+--------------------------------------------------- 
     1vs2 
2                    |   -0.501    -0.744    -0.258          1.38 
4                    |   -0.340    -0.592    -0.088          1.37 
5                    |   -0.063    -0.306     0.181          1.38 
54                   |   -0.360    -0.582    -0.138          1.41 
55                   |   -0.248    -0.469    -0.027          1.41 
 Sub-total           | 
  D+L pooled SMD     |   -0.302    -0.440    -0.164          6.94 
---------------------+--------------------------------------------------- 
     1vs4 
3                    |   -0.005    -0.219     0.209          1.42 
55                   |    0.109    -0.108     0.326          1.41 
 Sub-total           | 
  D+L pooled SMD     |    0.051    -0.101     0.204          2.83 
---------------------+--------------------------------------------------- 
     3vs5 
8                    |    0.283    -0.034     0.601          1.28 
56                   |   -0.040    -0.314     0.234          1.34 
 Sub-total           | 
  D+L pooled SMD     |    0.111    -0.205     0.427          2.62 
---------------------+--------------------------------------------------- 
     2vs5 
9                    |    0.379     0.153     0.604          1.40 
56                   |    0.672     0.388     0.956          1.32 
57                   |    0.251    -0.027     0.529          1.33 
70                   |    0.438     0.196     0.679          1.38 
 Sub-total           | 
  D+L pooled SMD     |    0.429     0.272     0.587          5.44 
---------------------+--------------------------------------------------- 
     2vs6 
10                   |    0.375     0.077     0.673          1.31 
11                   |    0.502     0.203     0.802          1.30 
58                   |    0.401     0.143     0.660          1.36 
 Sub-total           | 
  D+L pooled SMD     |    0.423     0.260     0.587          3.97 
---------------------+--------------------------------------------------- 
     3vs7 
15                   |    0.310    -0.467     1.086          0.68 
41                   |    0.393     0.058     0.728          1.25 
48                   |   -1.271    -1.956    -0.585          0.77 
 Sub-total           | 
  D+L pooled SMD     |   -0.173    -1.206     0.861          2.71 
---------------------+--------------------------------------------------- 
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2vs7 
16                   |    0.425     0.085     0.765          1.25 
17                   |    0.524     0.143     0.904          1.19 
59                   |    0.239    -0.002     0.481          1.38 
63                   |    0.663     0.416     0.909          1.38 
64                   |    0.628     0.378     0.877          1.37 
71                   |    0.478     0.197     0.758          1.33 
 Sub-total           | 
  D+L pooled SMD     |    0.493     0.354     0.633          7.89 
---------------------+--------------------------------------------------- 
     7vs9 
18                   |   -0.307    -0.557    -0.057          1.37 
21                   |   -0.142    -0.508     0.225          1.21 
59                   |   -0.141    -0.341     0.058          1.43 
 Sub-total           | 
  D+L pooled SMD     |   -0.196    -0.339    -0.052          4.01 
---------------------+--------------------------------------------------- 
     4vs7 
20                   |   -0.146    -0.332     0.040          1.45 
71                   |   -0.165    -0.644     0.314          1.04 
 Sub-total           | 
  D+L pooled SMD     |   -0.149    -0.322     0.025          2.49 
---------------------+--------------------------------------------------- 
     2vs10 
23                   |    0.846     0.604     1.088          1.38 
25                   |    0.609     0.353     0.865          1.36 
62                   |    0.487     0.254     0.721          1.39 
 Sub-total           | 
  D+L pooled SMD     |    0.646     0.436     0.857          4.14 
---------------------+--------------------------------------------------- 
     7vs10 
26                   |   -0.039    -0.255     0.177          1.41 
 Sub-total           | 
  D+L pooled SMD     |   -0.039    -0.255     0.177          1.41 
---------------------+--------------------------------------------------- 
     3vs9 
27                   |   -1.008    -1.817    -0.199          0.65 
 Sub-total           | 
  D+L pooled SMD     |   -1.008    -1.817    -0.199          0.65 
---------------------+--------------------------------------------------- 
     2vs9 
28                   |    0.229     0.023     0.435          1.42 
49                   |    0.128    -0.148     0.404          1.34 
59                   |    0.096    -0.148     0.340          1.38 
 Sub-total           | 
  D+L pooled SMD     |    0.162     0.026     0.299          4.14 
---------------------+--------------------------------------------------- 
     9vs12 
30                   |   -0.851    -1.603    -0.099          0.70 
 Sub-total           | 
  D+L pooled SMD     |   -0.851    -1.603    -0.099          0.70 
---------------------+--------------------------------------------------- 
     2vs12 
33                   |    0.497     0.304     0.690          1.44 
 Sub-total           | 
  D+L pooled SMD     |    0.497     0.304     0.690          1.44 
---------------------+--------------------------------------------------- 
     3vs8 
34                   |   -0.112    -0.829     0.604          0.74 
66                   |   -0.125    -0.516     0.266          1.17 
67                   |   -0.295    -0.616     0.026          1.27 
 Sub-total           | 
  D+L pooled SMD     |   -0.214    -0.449     0.020          3.18 
---------------------+--------------------------------------------------- 
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 2vs14 
35                   |    0.050    -0.224     0.324          1.34 
36                   |   -0.129    -0.399     0.141          1.34 
68                   |   -0.128    -0.394     0.138          1.35 
69                   |   -0.017    -0.277     0.243          1.36 
 Sub-total           | 
  D+L pooled SMD     |   -0.056    -0.190     0.077          5.39 
---------------------+--------------------------------------------------- 
     2vs16 
42                   |    0.410     0.151     0.668          1.36 
70                   |    0.612     0.367     0.856          1.38 
 Sub-total           | 
  D+L pooled SMD     |    0.515     0.317     0.713          2.74 
---------------------+--------------------------------------------------- 
     4vs12 
44                   |    0.047    -0.933     1.027          0.51 
46                   |    0.000    -0.877     0.877          0.59 
 Sub-total           | 
  D+L pooled SMD     |    0.021    -0.632     0.674          1.09 
---------------------+--------------------------------------------------- 
     3vs12 
47                   |   -0.360    -1.108     0.388          0.71 
52                   |   -0.097    -0.856     0.662          0.70 
 Sub-total           | 
  D+L pooled SMD     |   -0.230    -0.763     0.302          1.40 
---------------------+--------------------------------------------------- 
     1vs3 
54                   |   -0.061    -0.284     0.162          1.40 
 Sub-total           | 
  D+L pooled SMD     |   -0.061    -0.284     0.162          1.40 
---------------------+--------------------------------------------------- 
     2vs3 
54                   |    0.299     0.078     0.520          1.41 
56                   |    0.683     0.392     0.973          1.32 
66                   |    0.110    -0.273     0.494          1.18 
67                   |    0.330     0.012     0.648          1.28 
68                   |    0.445     0.180     0.710          1.35 
69                   |    0.454     0.190     0.718          1.35 
 Sub-total           | 
  D+L pooled SMD     |    0.400     0.263     0.537          7.88 
---------------------+--------------------------------------------------- 
     2vs4 
55                   |    0.368     0.144     0.591          1.40 
57                   |    0.677     0.390     0.963          1.32 
58                   |    0.944     0.673     1.214          1.34 
62                   |    0.452     0.216     0.689          1.39 
71                   |    0.548     0.061     1.034          1.03 
 Sub-total           | 
  D+L pooled SMD     |    0.593     0.375     0.812          6.49 
---------------------+--------------------------------------------------- 
     4vs5 
57                   |   -0.425    -0.706    -0.144          1.33 
 Sub-total           | 
  D+L pooled SMD     |   -0.425    -0.706    -0.144          1.33 
---------------------+--------------------------------------------------- 
     4vs6 
58                   |   -0.508    -0.722    -0.294          1.41 
 Sub-total           | 
  D+L pooled SMD     |   -0.508    -0.722    -0.294          1.41 
---------------------+--------------------------------------------------- 
     3vs4 
61                   |    1.110     0.334     1.887          0.68 
 Sub-total           | 
  D+L pooled SMD     |    1.110     0.334     1.887          0.68 
---------------------+--------------------------------------------------- 
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     3vs10 
61                   |    0.666    -0.072     1.404          0.72 
 Sub-total           | 
  D+L pooled SMD     |    0.666    -0.072     1.404          0.72 
---------------------+--------------------------------------------------- 
     4vs10 
61                   |   -0.444    -1.170     0.282          0.73 
62                   |    0.041    -0.186     0.269          1.40 
 Sub-total           | 
  D+L pooled SMD     |   -0.074    -0.479     0.331          2.13 
---------------------+--------------------------------------------------- 
     2vs11 
63                   |    0.494     0.250     0.737          1.38 
64                   |    0.342     0.091     0.592          1.37 
 Sub-total           | 
  D+L pooled SMD     |    0.420     0.245     0.594          2.75 
---------------------+--------------------------------------------------- 
     7vs11 
63                   |   -0.164    -0.366     0.039          1.43 
64                   |   -0.286    -0.487    -0.085          1.43 
 Sub-total           | 
  D+L pooled SMD     |   -0.225    -0.368    -0.083          2.86 
---------------------+--------------------------------------------------- 
     2vs8 
66                   |   -0.019    -0.312     0.275          1.31 
67                   |    0.015    -0.304     0.334          1.28 
 Sub-total           | 
  D+L pooled SMD     |   -0.003    -0.219     0.213          2.59 
---------------------+--------------------------------------------------- 
     3vs14 
68                   |   -0.564    -0.833    -0.294          1.34 
69                   |   -0.471    -0.734    -0.208          1.35 
 Sub-total           | 
  D+L pooled SMD     |   -0.516    -0.704    -0.328          2.70 
---------------------+--------------------------------------------------- 
     5vs16 
70                   |    0.167    -0.034     0.368          1.43 
 Sub-total           | 
  D+L pooled SMD     |    0.167    -0.034     0.368          1.43 
---------------------+--------------------------------------------------- 
Overall              |            
  D+L pooled SMD     |    0.139     0.054     0.224        100.00 
---------------------+--------------------------------------------------- 
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Test(s) of heterogeneity: 
               Heterogeneity  degrees of 
                 statistic     freedom      P    I-squared**   Tau-squared 
 
1vs2                 6.85          4      0.144     41.6%       0.0103 
1vs4                 0.53          1      0.465      0.0%       0.0000 
3vs5                 2.28          1      0.131     56.2%       0.0294 
2vs5                 4.58          3      0.205     34.5%       0.0089 
2vs6                 0.40          2      0.820      0.0%       0.0000 
3vs7                18.58          2      0.000     89.2%       0.7349 
2vs7                 7.37          5      0.195     32.1%       0.0097 
7vs9                 1.13          2      0.569      0.0%       0.0000 
4vs7                 0.01          1      0.942      0.0%       0.0000 
2vs10                4.47          2      0.107     55.3%       0.0191 
7vs10                0.00          0         .         .%       0.0000 
3vs9                 0.00          0         .         .%       0.0000 
2vs9                 0.74          2      0.690      0.0%       0.0000 
9vs12                0.00          0         .         .%       0.0000 
2vs12                0.00          0         .         .%       0.0000 
3vs8                 0.52          2      0.771      0.0%       0.0000 
2vs14                1.22          3      0.748      0.0%       0.0000 
13vs15               0.00          0         .         .%       0.0000 
2vs16                1.24          1      0.265     19.4%       0.0040 
4vs12                0.00          1      0.944      0.0%       0.0000 
3vs12                0.23          1      0.628      0.0%       0.0000 
1vs3                 0.00          0         .         .%       0.0000 
2vs3                 7.09          5      0.214     29.5%       0.0086 
2vs4                11.98          4      0.018     66.6%       0.0398 
4vs5                 0.00          0         .         .%       0.0000 
4vs6                 0.00          0         .         .%       0.0000 
3vs4                 0.00          0         .         .%       0.0000 
3vs10                0.00          0         .         .%       0.0000 
4vs10                1.56          1      0.211     36.0%       0.0424 
2vs11                0.73          1      0.393      0.0%       0.0000 
7vs11                0.71          1      0.400      0.0%       0.0000 
2vs8                 0.02          1      0.879      0.0%       0.0000 
3vs14                0.23          1      0.630      0.0%       0.0000 
5vs16                0.00          0         .         .%       0.0000 
Overall            574.86         80      0.000     86.1%       0.1214 
 
** I-squared: the variation in SMD attributable to heterogeneity. Note: 
between group heterogeneity not calculated; only valid with inverse 
variance method 
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Significance test(s) of SMD=0 
 
1vs2                  z=  4.29     p = 0.000 
1vs4                  z=  0.66     p = 0.508 
3vs5                  z=  0.69     p = 0.491 
2vs5                  z=  5.34     p = 0.000 
2vs6                  z=  5.08     p = 0.000 
3vs7                  z=  0.33     p = 0.743 
2vs7                  z=  6.94     p = 0.000 
7vs9                  z=  2.67     p = 0.008 
4vs7                  z=  1.68     p = 0.094 
2vs10                 z=  6.02     p = 0.000 
7vs10                 z=  0.35     p = 0.726 
3vs9                  z=  2.44     p = 0.015 
2vs9                  z=  2.33     p = 0.020 
9vs12                 z=  2.22     p = 0.027 
2vs12                 z=  5.06     p = 0.000 
3vs8                  z=  1.79     p = 0.073 
2vs14                 z=  0.83     p = 0.408 
13vs15                z=  1.15     p = 0.249 
2vs16                 z=  5.11     p = 0.000 
4vs12                 z=  0.06     p = 0.950 
3vs12                 z=  0.85     p = 0.397 
1vs3                  z=  0.54     p = 0.590 
2vs3                  z=  5.72     p = 0.000 
2vs4                  z=  5.33     p = 0.000 
4vs5                  z=  2.96     p = 0.003 
4vs6                  z=  4.65     p = 0.000 
3vs4                  z=  2.80     p = 0.005 
3vs10                 z=  1.77     p = 0.077 
4vs10                 z=  0.36     p = 0.720 
2vs11                 z=  4.71     p = 0.000 
7vs11                 z=  3.10     p = 0.002 
2vs8                  z=  0.03     p = 0.977 
3vs14                 z=  5.38     p = 0.000 
5vs16                 z=  1.63     p = 0.104 
Overall               z=  3.21     p = 0.001 
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Coherence for Continuous Response Outcome Excluding Studies with Combination 
Strategy 
-3 -2 -1 0 1 2 3
1st order loops
abc
acd
abd
bcg
bcd
bci
bce
bcj
bcl
bch
bcn
cdg
cgi
cgj
cde
cdj
cdl
cil
bdg
bgi
bgj
bgk
bde
bdf
bdj
bdl
bil
bep
dgj
Evaluation of coherence within first order closed loops
Estimates with 95% confidence intervals
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Code Name Code Name 
a Aripiprazole h  Lamotrigine 
b Placebo i Divalproex 
c Lithium j Risperidone 
d Haloperidol k Asenapine 
e Quetiapine l Carbamazepine 
f Ziprasidone n Topiramate 
g Olanzapine p Paliperidone 
 
 
  *-----  Evaluating the coherence of the network ------*  
 
  Nr of treatments:  14 
  Nr of all possible first order loops (triangles):  1680 
  Nr of available first order loops:  29  
  
 
 1 : Evaluation of the loop abc 
 Direct comparisons in the loop:  
 ab bc ac  
  5  6  1 
 
   Meta-analysis for the ab arm 
   mean(se)= -0.302(0.07) 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the ac arm 
   mean(se)= -0.061(0.114) 
   Indirect comparison for the ac arm 
   Mean(se)= 0.098(0.097) 
  
   Incoherence within the loop:  Mean(se)= 0.16(0.15) 
 
 
 2 : Evaluation of the loop acd 
 Direct comparisons in the loop:  
 ac cd ad  
  1  1  2 
 
   Meta-analysis for the ac arm 
   mean(se)= -0.061(0.114) 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the ad arm 
   mean(se)= 0.051(0.078) 
   Indirect comparison for the ad arm 
   Mean(se)= 1.049(0.412) 
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   Incoherence within the loop:  Mean(se)= 0.998(0.419) 
 
 
 3 : Evaluation of the loop abd 
 Direct comparisons in the loop:  
 ab bd ad  
  5  5  2 
 
   Meta-analysis for the ab arm 
   mean(se)= -0.302(0.07) 
   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Meta-analysis for the ad arm 
   mean(se)= 0.051(0.078) 
   Indirect comparison for the ad arm 
   Mean(se)= 0.291(0.131) 
  
   Incoherence within the loop:  Mean(se)= 0.24(0.152) 
 
 
 4 : Evaluation of the loop bcg 
 Direct comparisons in the loop:  
 bc cg bg  
  6  3  6 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the cg arm 
   mean(se)= -0.173(0.537) 
   Meta-analysis for the bg arm 
   mean(se)= 0.493(0.074) 
   Indirect comparison for the bg arm 
   Mean(se)= 0.227(0.541) 
  
   Incoherence within the loop:  Mean(se)= -0.266(0.546) 
 
 
 5 : Evaluation of the loop bcd 
 Direct comparisons in the loop:  
 bc cd bd  
  6  1  5 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Indirect comparison for the bd arm 
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   Mean(se)= 1.511(0.402) 
  
   Incoherence within the loop:  Mean(se)= 0.917(0.417) 
 
 
 6 : Evaluation of the loop bci 
 Direct comparisons in the loop:  
 bc ci bi  
  6  1  3 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the ci arm 
   mean(se)= -1.008(0.413) 
   Meta-analysis for the bi arm 
   mean(se)= 0.162(0.07) 
   Indirect comparison for the bi arm 
   Mean(se)= -0.608(0.418) 
  
   Incoherence within the loop:  Mean(se)= -0.77(0.424) 
 
 
 7 : Evaluation of the loop bce 
 Direct comparisons in the loop:  
 bc ce be  
  6  2  4 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the ce arm 
   mean(se)= 0.098(0.106) 
   Meta-analysis for the be arm 
   mean(se)= 0.429(0.077) 
   Indirect comparison for the be arm 
   Mean(se)= 0.498(0.125) 
  
   Incoherence within the loop:  Mean(se)= 0.069(0.147) 
 
 
 8 : Evaluation of the loop bcj 
 Direct comparisons in the loop:  
 bc cj bj  
  6  1  3 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the cj arm 
   mean(se)= 0.666(0.377) 
   Meta-analysis for the bj arm 
   mean(se)= 0.646(0.107) 
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   Indirect comparison for the bj arm 
   Mean(se)= 1.067(0.383) 
  
   Incoherence within the loop:  Mean(se)= 0.42(0.397) 
 
 
 9 : Evaluation of the loop bcl 
 Direct comparisons in the loop:  
 bc cl bl  
  6  2  1 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the cl arm 
   mean(se)= -0.23(0.272) 
   Meta-analysis for the bl arm 
   mean(se)= 0.497(0.098) 
   Indirect comparison for the bl arm 
   Mean(se)= 0.17(0.28) 
  
   Incoherence within the loop:  Mean(se)= -0.327(0.297) 
 
 
 10 : Evaluation of the loop bch 
 Direct comparisons in the loop:  
 bc ch bh  
  6  3  2 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the ch arm 
   mean(se)= -0.214(0.12) 
   Meta-analysis for the bh arm 
   mean(se)= -0.003(0.11) 
   Indirect comparison for the bh arm 
   Mean(se)= 0.186(0.137) 
  
   Incoherence within the loop:  Mean(se)= 0.189(0.176) 
 
 
 11 : Evaluation of the loop bcn 
 Direct comparisons in the loop:  
 bc cn bn  
  6  2  4 
 
   Meta-analysis for the bc arm 
   mean(se)= 0.4(0.067) 
   Meta-analysis for the cn arm 
   mean(se)= -0.516(0.096) 
   Meta-analysis for the bn arm 
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   mean(se)= -0.056(0.068) 
   Indirect comparison for the bn arm 
   Mean(se)= -0.116(0.117) 
  
   Incoherence within the loop:  Mean(se)= -0.059(0.136) 
 
 
 12 : Evaluation of the loop cdg 
 Direct comparisons in the loop:  
 cd dg cg  
  1  2  3 
 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the dg arm 
   mean(se)= -0.149(0.089) 
   Meta-analysis for the cg arm 
   mean(se)= -0.173(0.537) 
   Indirect comparison for the cg arm 
   Mean(se)= 0.962(0.406) 
  
   Incoherence within the loop:  Mean(se)= 1.135(0.673) 
 
 
 13 : Evaluation of the loop cgi 
 Direct comparisons in the loop:  
 cg gi ci  
  3  3  1 
 
   Meta-analysis for the cg arm 
   mean(se)= -0.173(0.537) 
   Meta-analysis for the gi arm 
   mean(se)= -0.196(0.073) 
   Meta-analysis for the ci arm 
   mean(se)= -1.008(0.413) 
   Indirect comparison for the ci arm 
   Mean(se)= -0.369(0.542) 
  
   Incoherence within the loop:  Mean(se)= 0.639(0.681) 
 
 
 14 : Evaluation of the loop cgj 
 Direct comparisons in the loop:  
 cg gj cj  
  3  1  1 
 
   Meta-analysis for the cg arm 
   mean(se)= -0.173(0.537) 
   Meta-analysis for the gj arm 
   mean(se)= -0.039(0.11) 
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   Meta-analysis for the cj arm 
   mean(se)= 0.666(0.377) 
   Indirect comparison for the cj arm 
   Mean(se)= -0.212(0.548) 
  
   Incoherence within the loop:  Mean(se)= -0.878(0.665) 
 
 
 15 : Evaluation of the loop cde 
 Direct comparisons in the loop:  
 cd de ce  
  1  1  2 
 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the de arm 
   mean(se)= -0.425(0.143) 
   Meta-analysis for the ce arm 
   mean(se)= 0.098(0.106) 
   Indirect comparison for the ce arm 
   Mean(se)= 0.686(0.421) 
  
   Incoherence within the loop:  Mean(se)= 0.588(0.434) 
 
 
 16 : Evaluation of the loop cdj 
 Direct comparisons in the loop:  
 cd dj cj  
  1  2  1 
 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the dj arm 
   mean(se)= -0.002(0.111) 
   Meta-analysis for the cj arm 
   mean(se)= 0.666(0.377) 
   Indirect comparison for the cj arm 
   Mean(se)= 1.108(0.411) 
  
   Incoherence within the loop:  Mean(se)= 0.442(0.558) 
 
 
 17 : Evaluation of the loop cdl 
 Direct comparisons in the loop:  
 cd dl cl  
  1  2  2 
 
   Meta-analysis for the cd arm 
   mean(se)= 1.11(0.396) 
   Meta-analysis for the dl arm 
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   mean(se)= 0.021(0.333) 
   Meta-analysis for the cl arm 
   mean(se)= -0.23(0.272) 
   Indirect comparison for the cl arm 
   Mean(se)= 1.131(0.518) 
  
   Incoherence within the loop:  Mean(se)= 1.361(0.585) 
 
 
 18 : Evaluation of the loop cil 
 Direct comparisons in the loop:  
 ci il cl  
  1  1  2 
 
   Meta-analysis for the ci arm 
   mean(se)= -1.008(0.413) 
   Meta-analysis for the il arm 
   mean(se)= -0.851(0.384) 
   Meta-analysis for the cl arm 
   mean(se)= -0.23(0.272) 
   Indirect comparison for the cl arm 
   Mean(se)= -1.859(0.564) 
  
   Incoherence within the loop:  Mean(se)= -1.629(0.626) 
 
 
 19 : Evaluation of the loop bdg 
 Direct comparisons in the loop:  
 bd dg bg  
  5  2  6 
 
   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Meta-analysis for the dg arm 
   mean(se)= -0.149(0.089) 
   Meta-analysis for the bg arm 
   mean(se)= 0.493(0.074) 
   Indirect comparison for the bg arm 
   Mean(se)= 0.445(0.142) 
  
   Incoherence within the loop:  Mean(se)= -0.049(0.16) 
 
 
 20 : Evaluation of the loop bgi 
 Direct comparisons in the loop:  
 bg gi bi  
  6  3  3 
 
   Meta-analysis for the bg arm 
   mean(se)= 0.493(0.074) 
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   Meta-analysis for the gi arm 
   mean(se)= -0.196(0.073) 
   Meta-analysis for the bi arm 
   mean(se)= 0.162(0.07) 
   Indirect comparison for the bi arm 
   Mean(se)= 0.298(0.104) 
  
   Incoherence within the loop:  Mean(se)= 0.135(0.125) 
 
 
 21 : Evaluation of the loop bgj 
 Direct comparisons in the loop:  
 bg gj bj  
  6  1  3 
 
   Meta-analysis for the bg arm 
   mean(se)= 0.493(0.074) 
   Meta-analysis for the gj arm 
   mean(se)= -0.039(0.11) 
   Meta-analysis for the bj arm 
   mean(se)= 0.646(0.107) 
   Indirect comparison for the bj arm 
   Mean(se)= 0.455(0.133) 
  
   Incoherence within the loop:  Mean(se)= -0.192(0.171) 
 
 
 22 : Evaluation of the loop bgk 
 Direct comparisons in the loop:  
 bg gk bk  
  6  2  2 
 
   Meta-analysis for the bg arm 
   mean(se)= 0.493(0.074) 
   Meta-analysis for the gk arm 
   mean(se)= -0.225(0.073) 
   Meta-analysis for the bk arm 
   mean(se)= 0.42(0.089) 
   Indirect comparison for the bk arm 
   Mean(se)= 0.268(0.104) 
  
   Incoherence within the loop:  Mean(se)= -0.152(0.137) 
 
 
 23 : Evaluation of the loop bde 
 Direct comparisons in the loop:  
 bd de be  
  5  1  4 
 
   Meta-analysis for the bd arm 
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   mean(se)= 0.593(0.11) 
   Meta-analysis for the de arm 
   mean(se)= -0.425(0.143) 
   Meta-analysis for the be arm 
   mean(se)= 0.429(0.077) 
   Indirect comparison for the be arm 
   Mean(se)= 0.169(0.181) 
  
   Incoherence within the loop:  Mean(se)= -0.26(0.197) 
 
 
 24 : Evaluation of the loop bdf 
 Direct comparisons in the loop:  
 bd df bf  
  5  1  3 
 
   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Meta-analysis for the df arm 
   mean(se)= -0.508(0.109) 
   Meta-analysis for the bf arm 
   mean(se)= 0.423(0.083) 
   Indirect comparison for the bf arm 
   Mean(se)= 0.085(0.155) 
  
   Incoherence within the loop:  Mean(se)= -0.338(0.176) 
 
 
 25 : Evaluation of the loop bdj 
 Direct comparisons in the loop:  
 bd dj bj  
  5  2  3 
 
   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Meta-analysis for the dj arm 
   mean(se)= -0.002(0.111) 
   Meta-analysis for the bj arm 
   mean(se)= 0.646(0.107) 
   Indirect comparison for the bj arm 
   Mean(se)= 0.591(0.156) 
  
   Incoherence within the loop:  Mean(se)= -0.055(0.19) 
 
 
 26 : Evaluation of the loop bdl 
 Direct comparisons in the loop:  
 bd dl bl  
  5  2  1 
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   Meta-analysis for the bd arm 
   mean(se)= 0.593(0.11) 
   Meta-analysis for the dl arm 
   mean(se)= 0.021(0.333) 
   Meta-analysis for the bl arm 
   mean(se)= 0.497(0.098) 
   Indirect comparison for the bl arm 
   Mean(se)= 0.614(0.351) 
  
   Incoherence within the loop:  Mean(se)= 0.117(0.365) 
 
 
 27 : Evaluation of the loop bil 
 Direct comparisons in the loop:  
 bi il bl  
  3  1  1 
 
   Meta-analysis for the bi arm 
   mean(se)= 0.162(0.07) 
   Meta-analysis for the il arm 
   mean(se)= -0.851(0.384) 
   Meta-analysis for the bl arm 
   mean(se)= 0.497(0.098) 
   Indirect comparison for the bl arm 
   Mean(se)= -0.689(0.39) 
  
   Incoherence within the loop:  Mean(se)= -1.186(0.402) 
 
 
 28 : Evaluation of the loop bep 
 Direct comparisons in the loop:  
 be ep bp  
  4  1  2 
 
   Meta-analysis for the be arm 
   mean(se)= 0.429(0.077) 
   Meta-analysis for the ep arm 
   mean(se)= 0.167(0.103) 
   Meta-analysis for the bp arm 
   mean(se)= 0.516(0.091) 
   Indirect comparison for the bp arm 
   Mean(se)= 0.596(0.128) 
  
   Incoherence within the loop:  Mean(se)= 0.079(0.157) 
 
 
 29 : Evaluation of the loop dgj 
 Direct comparisons in the loop:  
 dg gj dj  
  2  1  2 
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   Meta-analysis for the dg arm 
   mean(se)= -0.149(0.089) 
   Meta-analysis for the gj arm 
   mean(se)= -0.039(0.11) 
   Meta-analysis for the dj arm 
   mean(se)= -0.002(0.111) 
   Indirect comparison for the dj arm 
   Mean(se)= -0.187(0.141) 
  
   Incoherence within the loop:  Mean(se)= -0.185(0.18) 
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SUCRAs and rankograms 
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Bayesian posterior probabilities can be used to rank the treatments for each 
outcome. For example one can estimate for each treatment what is the 
probability to be the best (most effective or most acceptable) and also calculate 
the probability to be the second best, third best and so on. Plots of these rank 
probabilities (rankograms) are useful, but unlikely to provide a ranking 
measure when many treatments are competing. Another way would be to 
estimate the cumulative probabilities, i.e. the probability of each treatment to be 
the best, among the best two options, among the best three options etc. These 
probabilities can be plotted against the possible ranks. These plots are presented 
below together with the rankograms. Obviously, the larger the surface below 
the cumulative ranking curve, the more probable are the lowest ranks, i.e. the 
more effective or acceptable the treatment. The surface below the cumulative 
ranking curve (SUCRA) can be quantified. The following tables show the mean 
SUCRA values together with the 95% CrI for each outcome and model.  
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Acceptability (dropout) data - Rankograms
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 Continuous Response 
 
 
1.1 Comparing SUCRAs values 
 
 
Drug  Split 
 
Combined 
 Mean 95% CrI Mean 95% CrI 
Aripiprazole 0.635  0.646  
Placebo 0.144  0.155  
Lithium 0.636  0.653  
Haloperidol 0.948  0.966  
Quetiapine 0.599  0.642  
Ziprasidone 0.343  0.365  
Olanzapine 0.777  0.779  
Lamotrigine 0.227  0.242  
Divalproex 0.355  0.372  
Risperidone 0.945  0.895  
Asenapine 0.514  0.527  
Carbamazepine 0.613  0.628  
Topiramate 0.085  0.092  
Gabapentin 0.031  0.034  
Paliperidone 0.647  - - 
 
 
 Continuous Response with No Combo 
2.2 Comparing SUCRA values 
 
 
Drug  Split 
 
Combined 
 Mean 95% CrI Mean 95% CrI 
Aripiprazole 0.556  0.586  
Placebo 0.081  0.088  
Lithium 0.544  0.576  
Haloperidol 0.935  0.960  
Quetiapine 0.607  0.659  
Ziprasidone 0.468  0.489  
Olanzapine 0.746  0.772  
Lamotrigine 0.157  0.170  
Divalproex 0.277  0.296  
Risperidone 0.921  0.922  
Asenapine 0.438  0.462  
Carbamazepine 0.460  0.488  
Topiramate 0.028  0.030  
Gabapentin - - - - 
Paliperidone 0.780  - - 
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 Binary Response 
 
3.2 Comparing SUCRAs values 
 
 
Drug  Split 
 
Combined 
 Mean 95% CrI Mean 95% CrI 
Aripiprazole 0.574  0.599  
Placebo 0.087  0.098  
Lithium 0.473  0.484  
Haloperidol 0.766  0.761  
Quetiapine 0.552  0.605  
Ziprasidone 0.245  0.254  
Olanzapine 0.717  0.718  
Lamotrigine 0.380  0.396  
Divalproex 0.596  0.590  
Risperidone 0.826  0.691  
Asenapine 0.466  0.454  
Carbamazepine 0.781  0.780  
Topiramate 0.076  0.068  
Gabapentin - - - - 
Paliperidone 0.460  - - 
 
 
 
 Binary Drop 
4.2 Comparing SUCRAs values 
 
Drug  Split 
 
Combined 
 Mean 95% CrI Mean 95% CrI 
Aripiprazole 0.627  0.650  
Placebo 0.314  0.333  
Lithium 0.327  0.343  
Haloperidol 0.499  0.520  
Quetiapine 0.782  0.811  
Ziprasidone 0.434  0.453  
Olanzapine 0.879  0.902  
Lamotrigine 0.231  0.243  
Divalproex 0.656  0.682  
Risperidone 0.848  0.860  
Asenapine 0.369  0.383  
Carbamazepine 0.582  0.601  
Topiramate 0.086  0.091  
Gabapentin 0.122  0.126  
Paliperidone 0.740  - - 
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Appendix 11 
 
 
Meta-regression analysis 
 
 
 
 
 
135 
 
Meta-regression analysis for Continuous and Dropouts response 
 
 
Sponsored drugs often appear to be more efficacious and acceptable when a company 
decides to fund a drug then it intends to have high efficacy or/ and acceptability. 
Through meta-regression we want to “uncover” the true relative effectiveness of each 
drug taking into consideration its sponsorship status (that is, whether it is sponsored or 
not compared to the baseline). After applying meta-regression we expect the efficacy 
of sponsored drugs to decrease compared to placebo and dropout rate to increase. 
 
 Continuous Response  
The meta-regression model is the below 
 
where  
=  is the observed (unadjusted) standardized mean 
difference when we compare the  drug with the first drug (which is supposed to 
be the baseline treatment) independently of the sponsorship status. 
 
 is the covariate we examine 
for publication bias and 
 is the (adjusted for the sponsorship standardized mean difference) efficacy of the 
 drug in comparison with the first drug according to the sponsorship status of 
the  drug, . So,  means that the  drug is better; the lower the 
effect size Θ_1k thebetter for drug k 
 
Running WinBUGS in 100000 iterations and excluding the results from the first 10001 
iterations we estimated that  with 95% CrI . The 
positive sign of this regression coefficient implies that the difference between the 
mean response of the  treatment’s effect and the mean response of the baseline 
treatment’s effect tends to increase, when the  treatment is sponsored.  
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    The SMDs after adjusting for sponsorship compared to placebo are 
 
 Adjusted Unadjusted 
SMD mean 95% CrI mean 95% CrI 
Aripiprazole -0.3386 [-0.5341, -0.1349] -0.3710 [-0.5082, -0.2329] 
Lithium -0.3766 [-0.5061, -0.2474] -0.3742 [-0.503, -0.247] 
Haloperidol -0.5615 [-0.6889, -0.4325] -0.5592 [-0.6862, -0.431] 
Quetiapine -0.3458 [-0.5274,-0.1591] -0.3691 [-0.5133, -0.2281] 
Ziprasidone -0.1631 [-0.384, 0.06193] -0.1962 [-0.3664, -0.03014] 
Olanzapine -0.4077 [0.2354, 0.5684] -0.4346 [-0.5433, -0.3235] 
Lamotrigine -0.0509 [-0.3485, 0.2461] -0.0777 [-0.3381,0.1824] 
Divalproex -0.1831 [-0.3668, 0.00554] -0.2036 [-0.3698,-0.03554] 
Risperidone -0.4724 [-0.6526, -0.2876] -0.5034 [-0.6272, -0.3807] 
Asenapine -0.2513 [-0.5719, 0.07131] -0.3000 [-0.5315, -0.06895] 
Carbamazepine -0.3349 [-0.5961, -0.07501] -0.3575 [-0.594, -0.1083] 
Topiramate 0.1071 [-0.114, 0.3338] 0.0752 [-0.09268, 0.2418] 
Gabapentin 0.3532 [-0.1722, 0.8797] 0.3224 [-0.1788, 0.823] 
 
The relative effectiveness of the all active treatments is dropping compared to placebo 
after adjustment. 
 
 Binary Dropout Response  
 
The meta-regression model is the below 
 
where  
 is the observed (unadjusted) log odds ratio when we 
compare the  drug with the first drug (reference in the trial)  
 is the covariate we examine 
for sponsorship bias and 
 is the acceptability of the  drug in comparison with the first drug of each 
trial  according to the sponsorship status of the  drug, . 
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Running WinBUGS in 100000 iterations and excluding the results from the first 10001 
iterations we found that   with 95% CI . The coefficient 
is very imprecise and centered at. The negative sign of this regression coefficient 
implies that the difference between the log odds of the  treatment’s effect and 
the log odds of the first treatment’s effect tends to decrease when the  treatment 
is sponsored, meaning that the acceptability of the sponsored treatment is downplayed 
in the observed estimates. 
 
 
 Adjusted Unadjusted 
OR mean 95% CrI mean 95% CrI 
Aripiprazole 0.6930 [0.4411, 1.1525] 0.7479 [0.5464, 1.0547] 
Lithium 0.9681 [0.7252, 1.3371] 0.9950 [0.7380, 1.3797] 
Haloperidol 0.8217 [0.6131, 1.1370] 0.8418 [0.6266, 1.1618] 
Quetiapine 0.5845 [0.3827, 0.9425] 0.6297 [0.4507, 0.9050] 
Ziprasidone 0.8340 [0.5051, 1.4575] 0.8913 [0.6139, 1.3362] 
Olanzapine 0.5345 [0.3642, 0.8271] 0.5760 [0.4442, 0.7599] 
Lamotrigine 1.0543 [0.5559, 2.2568] 1.1392 [0.6506, 2.1810] 
Divalproex 0.7082 [0.4805, 1.0889] 0.7194 [0.5081, 1.0547] 
Risperidone 0.5618 [0.3630, 0.9091] 0.5981 [0.4403, 0.8319] 
Asenapine 0.8460 [0.4205, 1.9650] 0.9515 [0.5659, 1.7188] 
Carbamazepine 0.7294 [0.4203, 1.4029] 0.7530 [0.4403, 1.4049] 
Topiramate 1.3721 [0.8271, 2.4540] 1.4605 [0.9901, 2.2482] 
Gabapentin 1.4302 [0.5435, 5.2743] 1.5293 [0.6143, 5.1099] 
 
 
 
Checking model fit using deviances 
 
The fit of each model can be evaluated using the posterior mean of the residual deviance 
 and the Deviance Information Criterion (DIC). A model has good fit when the residual 
deviance approximates the number of data points. 
References: 
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Comparison of different models can be accomplished by comparing DICs; low DIC 
values signify a better model when both fit and parsimony are considered. To check 
individual points’ contributions to the DIC, for each data point, we plot the leverage (the 
difference between posterior residual deviance and the deviance at the posterior mean of 
the fitted value) against the square root of the posterior residual deviance. We identify 
data points as contributing to the model’s poor fit if they lie outside the 
borders in the leverage plots. 
 
(Continuous response) 
Fit of the model
Residual Deviance (postDi)
L
e
v
e
ra
g
e
 (
p
D
i)
1.0 1.5 2.0 2.5
1
2
3
4
5
6
 
*Model fit measures and diagnostics* 
Residual deviance:   > 141  
Data points= 141  
(Note that total residual deviance should approximate the number of data points for a  
good fit)  
Effective number of parameters: 141.76   
DIC= 299.28  
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 (Binary response) 
Fit of the model
Residual Deviance (postDi)
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*Model fit measures and diagnostics* 
Residual deviance:  > 105  
Data points= 105  
(Note that total residual deviance should approximate the number of data points for a  
good fit)  
Effective number of parameters= 81.66  
DIC= 192.01  
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(Dropouts response) 
We have already excluded Chlorpromazine, Pimozide and Thiothixene 
Fit of the model
Residual Deviance (postDi)
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*Model fit measures and diagnostics*  
Residual deviance: 149.16  > 144  
Data points= 144  
(Note that total residual deviance should approximate the number of data points for a  
good fit)  
Effective number of parameters= 111.33  
DIC= 260.49  
 
 
 
 
 
 
 
 
